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1. INTRODUCTION 
 
1.1. Oral Drug Delivery System: -                    (Chien Y. W., 2009; Shojaei A.H., 1998)
 
            For decades, per oral drug delivery has been the most widely utilized route of 
administration for the systemic delivery of drugs. The lack of efficacy of certain drugs 
due to decreased bioavailability, unpredictable and erratic absorption, GI intolerance 
or pre-systemic elimination has prompted the examination of other potential routes for 
administration. Moreover, the recent development of a large number of peptides as 
drugs has intensified investigation of mucosal delivery of drugs. Such routes 
exploring other absorptive mucosa include the oral, nasal, buccal, rectal, vaginal and 
ocular to a limited extend, pulmonary routes amongst the various route of drug 
delivery, oral route is perhaps the most preferred to the patient and the clinician alike. 
However, per oral administration of drugs has disadvantages such as hepatic first pass 
metabolism and enzymatic degradation within the GIT, that prohibit oral 
administration of certain classes of drugs especially peptides and proteins. 
Consequently, other absorptive mucosal are considered as potential sites for drug 
administration. 
Trans mucosal route of drug delivery offer distinct advantages over peroral 
administration for systemic drug delivery. These advantages include possible bypass 
of first pass effect, avoidance of pre systemic elimination within the GIT and 
depending on the particular drug, a better enzymatic flora for drug absorption. The 
nasal cavity as a site for drug delivery has been investigated by many researchers and 
the route already reached commercial status with several drug including LHRH and 
calcitocin. However, the potential irritation and the reversible damage to the ciliary 
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action of the nasal cavity from chronic application of nasal dosage forms, as well as 
the large intra-and inter-subject variability in mucus secretion in the nasal mucosa, 
could significantly affect drug absorption from this site. Even though the rectal, 
vaginal and ocular mucosa all offer certain advantages, the poor patient acceptability 
associated with these sites renders them reserved for local application rather than 
systemic drug administration  
            As a site for drug delivery, the oral cavity offers several advantages over the 
gastrointestinal route and other alternative routes of drug administration. The 
membranes that line the oral cavity are readily accessible, robust and exhibit fast 
cellular recovery following local stress and damage. Oral mucosal drug delivery 
systems are easy and painless to administer and well accepted by the patient. Precise 
dosage form localization is possible and there is the ability to terminate delivery when 
required thus, patients could conceivably control the period of administration. For 
patient suffering with nausea or vomiting or in a state of unconsciousness with an 
upper GIT disease or surgery which affect oral drug absorption or those who have 
difficulty in swallowing per oral medications, the oral cavity may be useful site for 
drug delivery. The unique environment of the oral cavity dictates its potential as a site 
for drug delivery. The oral mucosa is highly perfused with blood vessels. It has a high 
blood flow of 20-50 mL/min. Because of the rich blood supply and direct access to 
the systemic circulation, the oral mucosal route is suitable for drugs which are 
susceptible to acid hydrolysis in the stomach or which are extensively metabolized in 
the liver. The continual secretion of saliva results in rapid removal of released drug 
and this may dictate that the oral cavity should be restricted to the delivery of drugs 
which have a short systemic action. 
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Conventional formulations for local oral delivery are principally lozenges, 
mouthwashes, mouth paints, oral gels, pastes and suspensions. Release of drugs from 
these preparations involves an initial burst of activity, whose level rapidly declines to 
sub-therapeutic concentrations. Retentive buccal mucoadhesive formulations may 
prove to be a viable alternative to the conventional oral medications as they can be 
readily attached to the buccal cavity, retained for a longer period of time and removed 
at any time. Attempts have been made earlier to formulate various mucoadhesive 
devices including Film, films, patches, disks, strips, ointments and gels. Buccal 
delivery of drugs provides an attractive alternative to the oral route of drug 
administration, particularly in overcoming deficiencies associated with the latter mode 
of dosing. Problems such as high first-pass metabolism and drug degradation in the 
harsh gastrointestinal environment can be circumvented by administering the drug via 
the buccal route. Moreover, buccal drug delivery offers a safer method of drug 
utilization, since drug absorption can be promptly terminated in cases of toxicity by 
removing the dosage form from the buccal cavity. It is also possible to administer 
drugs to patients who cannot be dosed orally via this route. Therefore, adhesive 
mucosal dosage forms were suggested for oral delivery, which included adhesive 
Film, adhesive gels and adhesive patches. A suitable buccal drug delivery system 
should be flexible and possess good bioadhesive properties, so that it can be retained 
in the oral cavity for the desired duration. In addition, it should release the drug in a 
controlled and predictable manner to elicit the required therapeutic response. 
Hydrogels are able to meet these requirements and they swell to a certain extent when 
placed in aqueous medium. 
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Of the range of pharmaceutical preparations available for administration into 
the oral cavity, the most popular form is that of a rapidly dissolving film that releases 
its drug contents for absorption across the oral mucosa. Alternatively, a film or 
capsule can be chewed to release its contents. This later method is less successful 
because mastication tends to produce a large volume of saliva that increases the 
probability of premature swallowing. The same problem occurs in the administration 
of drug in the form of a chewing gum. 
1.2. Mucoadhesive Drug Delivery System:- 
                                               (Bhalodia R. et al., 2010; Gattani S. G. et al., 2006) 
Mucoadhesive drug delivery system is a new system of drug delivery and has 
recently gained great concern in pharmaceutical sciences.  The concept of 
mucoadhesives was introduced in the early 1980s. Residencecan be defined as the 
phenomenon of the attachment of natural or synthetic polymers to a mucosal surface. 
In general, the process involved in the Residence phenomenon can be described in 
three steps: first of all, the wetting and swelling of the polymer should allow an 
intimate contact with the tissue and secondly, interpenetration of the polymer chains 
and entanglement between the polymer and the mucin chains should be attained and 
finally, the formation of weak chemical bonds. Mucus is a viscous and heterogeneous 
biological product that coats many epithelial surfaces. Mucus-secreting cells are 
widely spread in different locations in the body, including the nasal, ocular, buccal 
area and the gastrointestinal, reproductive and respiratory tracts. Mainly, the mucus 
serves as a lubricant to minimize shear stresses and as a protection barrier against 
harmful substances. However, mucus can perform other important functions. Goblet 
cells located in the epithelium are unicellular mucus-secreting glands. Mucus is stored 
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in large granules in the goblet cell and can be released by exocytosis or exfoliation of 
the whole cell. Mucus granules are mainly stored in the apical side of the goblet cell, 
which results in the characteristic balloon shape of these cells. Although the secretion 
of mucus can vary depending on age, sex, body location and health condition, the 
average mucus turnover is approximately 6 h. Mucus consists mainly of water (up to 
95% weight), inorganic salts (about 1% weight), carbohydrates and lipids (less than 
1%) and glycoproteins (no more than 5% weight). Mucus glycolproteins are also 
called mucins and consist of a protein core with branched oligosaccharide chains 
attached over 63% of its length. Approximately 80% by weight of the glycoprotein 
consists of oligosaccharides, which make the mucin more hydrosoluble and also 
protects the protein core from proteolytic degradation. 
 
Fig. 1.1. Mucus layer on epithelial surface. 
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Mucus is a thin blanket covering all epithelia that are in contact with the 
external environment in the gastrointestinal, respiratory and urogenital tracts. In each 
case of these mucosal routes, mucus characteristics and functions are different. By 
this definition, the mucosal routes for drug delivery are: 
1) Buccal drug delivery system 
2) Nasal drug delivery system 
3) Ocular drug delivery system 
4) Vaginal drug delivery system 
5) Gastrointestinal drug delivery system  
1.2.1. Buccal Drug Delivery System:  
    (Prachiti P. V. et al., 2006; Rathbone M.J. et al., 1996; Vyas S. and Khar R. K., 2002) 
             The oral cavity is viewed as a convenient and easily accessible site for the 
delivery of therapeutic agents. Within the oral cavity, drugs can be administered from 
the buccal gingiva or the sublingual space either for the treatment of local conditions         
(eg. thrush) or for the systemic treatment of diseases (eg. angina). The advances in 
bioadhesive and controlled release technology have stimulated a renewal of interest in 
the delivery of drugs to, or via the buccal route. 
           The buccal route of drug administration is the most widely used method for 
application of mucoadhesive delivery system. Both for the local treatment of 
infflamation and for rapid absorption of compounds, formulation technology have 
employed the buccal route for over two decades. The oral mucosa is covered by 
stratified squamous epithelium and three different types of mucosa can be 
distinguished: The masticatory, the lining and the specialized mucosa. Blood supply 
to the oral cavity tissues is delivered via the external carotid artery. The buccal 
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mucosa lines the inner cheek and buccal formulations are placed in the mouth 
between the upper gingivae (gums) and cheek (sometimes referred as buccal pouch) 
to treat local and systemic conditions. 
            Relative to the nasal and rectal routes, the buccal mucosa has low enzymatic 
activity and drug inactivation occurring biochemical degradation is not as rapid and 
extensive. The oral cavity consists of pair of buccal mucosa. Thus, a drug delivery 
system can be applied at various sites on the same mucosa or alternatively on the left 
or right buccal mucosa on different application. A buccal drug delivery system is 
applied to a specific area on the buccal membrane. Moreover the delivery system can 
be designed to the unidirectional in drug release, so that it can be protected from the 
local environment of the oral cavity. Within a oral mucosal cavity, delivery of drugs is 
classified into three categories: 
1) Sublingual delivery – In this the systemic delivery of drugs through the 
mucosal membranes lining the floor of the mouth. This gives very fast onset 
of action of the drug but duration is usually short. 
2) Buccal delivery – In this the drug administration through the mucosal 
membranes lining the cheeks (buccal mucosa) for buccal absorption, the 
buccal sulcus is used. This is the area between the upper lip and the gum. 
Film formulated for absorption from the buccal sulcus give a quick onset of 
action but will also give a longer duration of action than the sublingual 
route. 
3) Local delivery – Which is the drug delivery into the oral cavity. The local 
delivery used for the treatment of toothache, periodontal diseases, dental 
caries, bacterial and fungal infections. 
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        These sites differ from each other in terms of their anatomy and permeability. 
The sublingual mucosa is relatively permeable, giving rapid absorption and 
acceptable bioavailabilities of many drugs and is convenient, accessible and generally 
well accepted. The buccal membrane is sufficiently large to allow a delivery system to 
be placed at different sites on the same membrane on different occasions. This may be 
advantageous if the drug components of the delivery system or other excipients 
include in the formulation reversibly damage or irritate the mucosa. The oral cavity 
thus, on the other hand is highly acceptable by patients, the mucosa is relatively 
permeable with a rich blood supply, it is robust and shows short recovery times after 
stress or damage and the virtual lack of langerhans cells make the oral mucosa 
tolerant to potential allergens. These factors make the oral mucosal cavity a very 
attractive and feasible site for systemic drug delivery. 
Table 1.1: Comparative properties of gastrointestinal, dermal and transmucosal drug 
administration
 
 
Gastrointestinal Dermal Nasal 
Oral 
mucosal 
Vaginal 
Accessibility + +++ ++ ++ + 
Surface area +++ +++ + ++ +++ 
Surface 
Enviornment 
+ ++ ++ +++ + 
Permiability +++ + +++ ++ +++ 
Reactivity ++ ++ + +++ ++ 
Vascular 
Drainage 
+++ + +++ ++ +++ 
First pass 
clearance 
+ +++ +++ +++ + 
Patient 
acceptability 
++ +++ ++ +++ +++ 
   + Poor, + + Good, + + + Excellent 
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1.2.2. Advantages of Buccal Drug Delivery System:      (Bandyopadhyay A. K., 2008) 
1) Ease of administration and termination of therapy. 
2) Permits localization of drugs to the oral cavity for prolonged period of time can 
be administered to unconscious patients. 
3) There is relatively quick onset of action. 
4) A significant reduction in dose can be achieved thereby reducing dose dependent 
side effects. 
5) Presence of saliva facilitates both drug dissolution and its subsequent permeation 
by keeping the oral mucosa moist. 
6) This route can be used for administration of drugs, which are unstable at acidic 
environment of the stomach or are destroy by the enzymatic flora. 
7) The drug enters the general circulation without first passing through the liver.   
8) Excellent accessibility to the buccal mucosa makes application of dosage form 
painless. 
9) The delivery system can be designed to the unidirectional in drug release. So that 
it can be protected from the local environment of the oral cavity. 
10) The buccal mucosa has low enzymatic activity and drug inactivation owing 
biochemical degradation is not as rapid and extensive. 
1.2.3. Ideal Properties of Buccal Mucosal Drug Delivery: 
                                                                                                (Bandyopadhyay A. K., 2008) 
1) It should adhere to the site of attachment for a few hours. 
2) It should release the drug in a controlled fashion. 
3) It should provide drug release in an unidirectional way toward the mucosa. 
4) It should facilitate the rate and extent of drug absorption. 
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5) It should not cause any irritation or inconvenience to the patient. 
6) It should not interfere with the normal functions such as talking, drinking etc. 
1.2.4. Limitations of Buccal Drug Delivery:                            (Bhalodia R.et al., 2010) 
Drug administration via this route has certain limitations: 
1) The surface area available for absorption in the buccal mucosa is much smaller 
than gastrointestinal, nasal, rectal and vaginal mucosae. 
2) The buccal mucosa continuously bathed by saliva hence lowering the 
concentration of drug at absorbing site. 
3) This route cannot administer drugs, which are unstable at buccal pH. 
4) Drugs, which irritates buccal mucosa or have a bitter unpleasant taste or an 
obnoxious odour cannot administer by this route. 
5) Because of the limited surface area, only a small dose can be administered. 
6) Production of large volume of saliva increases the probability of premature 
swallowing. 
1.3. Reported Mucoadhesive Buccal Dosage Forms:- 
                                                                     (Johnston T. P. et al., 2005; Sinko P.J., 2006)  
Over the last 20 years a wide range of formulations has been developed for 
buccal drug delivery (Film, Discs, Patches, Gels, Ointments, Chewing gum and 
Mouthwashes) but comparatively few have found their way into the market. Buccal 
formulations have been developed to allow prolonged localized therapy and enhanced 
systemic delivery. 
The most common formulations are Film and patches. Such formulations must 
be of a small size and a suitable geometry so as not to interfere with physiological 
function of the mouth, even after their hydration in the oral cavity. Moreover, in the 
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case of transmucosal administration, drug release should be unidirectional (towards 
the mucosa) and the release into the saliva should be avoided. Bioadhesive devices are 
broadly classified as, 
1.3.1. Solid Buccal Adhesive Dosage Forms:- 
1) Buccal Tablet:                               (Gaurav Kumar Sharma et al.,2012) 
 These are solid dosage forms prepared by the compression of powder mix that 
can be placed into contact with the oral mucosa and allow to adhere. They can deliver 
drug multidirectional into the oral cavity or to the mucosal surface. Alternatively, the 
presence of an impermeable layer can ensure that drug is delivered unidirectional. For 
systemic therapy, they will hold a drug in intimate contact with its absorbing surface, 
offer some protection to enzymatic degradation and avoid first pass metabolism. For 
local action, the formulation can be applied directly to a specific region. A typical 
bioadhesive formulation consists of a bioadhesive   polymer (such as polyacrylic acids 
or a cellulose derivative) alone or in combination is incorporated into a matrix 
containing the active agent and excipients and perhaps the second layer to allow 
unidirectional drug delivery. 
       Table 1.2: Buccoadhesive Tablet containing bioadhesive polymers and Drugs 
Sr. 
No. 
Type of 
Formulation 
Bioadhesives polymers Drugs 
1 Bilayer tablet 
Sodium Alginate Carbopol 934 P, 
Ethyl Cellulose 
Propranolol 
Hydrochloride 
2 Matrix tablet 
Methocel K4M, Carbopol 934 P, 
Ethyl Cellulose 
Metaprolol 
Tartrate 
3 Matrix tablet 
Sodium CMC, HPMC,  
Carbopol 934 P 
Prednisolone 
4 Matrix tablet 
Sodium CMC, HPMC K4M, 
Carbopol 934 P, HPMC K15M 
Ondansetron 
Hydrochloride 
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2) Lozenges: 
Bioadhesive lozenges may be used for the delivery of drugs that act topically 
within the mouth including antimicrobials, corticosteroids, local anesthetics, 
antibiotics and antifungal. Conventional lozenges produce a high initial release of 
drug in the oral cavity, which rapidly declines to sub therapeutic levels, thus multiple 
daily dosing is required. A slow release bioadhesive lozenge offers the potential for 
prolonged drug release with improved patient compliance. Codd and Deasy 
investigated bioadhesive lozenges as a means to deliver antifungal agents to the oral 
cavity. 
1.3.2. Semi-Solid Buccal Adhesive Dosage Forms:- 
These typically contain a bioadhesive polymers and drug plus any required 
excipients dissolved or suspended as a fine powder in an aqueous or non aqueous 
base, depending on their solubility and concentration. They can be applied by using 
the finger (or syringe) to a target region and tend to be more acceptable in terms of 
mouth fill to patients relative to a solid dosage form. However, they may deliver 
varying amount of active ingredients in comparison with a unit dosage form. 
1) Films and Patches: 
Patches are usually prepared by casting a solution of the polymer, drug and 
any excipients (such as plasticizer) on to a surface and allowing it to dry. Patches can 
be made ≤ 10-15 cm2 in size but are more usually 1-3 cm2 with perhaps an ellipsoid 
shape to fit comfortably into the centre of the buccal mucosa. In similar fashion to 
buccal Film, they can be made multidirectional or unidirectional. Patches are 
laminated and generally consist of an impermeable backing layer and a drug-
containing layer that has mucoadhesive properties and from which the drug is released 
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in a controlled manner. Systems based on diclofenac, tannic and boric acids and 
intended for local administration have been developed. Due to relative thinness of the 
films, they are more susceptible to overhydration and loss of adhesive properties. 
Flexible films may be used to deliver drugs directly to a mucosalmembrane. They also 
offer advantages over creams and ointments in terms of delivery of measured dose of 
drug to the site. Buccal adhesive films are already available in market eg. Zilactin 
used for the therapy of canker sores, cold sores and lip sores. 
Table 1.3: Semi-solid buccal adhesive dosage forms containing bioadhesive polymers 
and active agents. 
 
2) Gel: 
Gel forming bioadhesive polymers include crosslinked polyacrylic acid that 
has been used to adhere to mucosal surfaces for extended period of time and provide 
controlled release of drug at the absorption site. A limitation of gel formulations lies 
on their inability to deliver a measured dose of drug to the site. They are therefore of 
limited use for drugs with narrow therapeutic window. 
 
Sr. No. 
Type of 
formulation 
Bioadhesives Active agent 
1 Film Na CMC, PVP K-50 
Diltiazem 
hydrochloride 
2 Patch 
Na CMC, HPMC K4M, 
Chitosan, HPMC K15M 
Miconazole 
nitrate 
3 Patch 
Polycarbophil, 
Carbopol940, Xanthan 
gum 
Benzydamine and 
Lidocaine 
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Table 1.4: Semi-solid buccaladhesive dosage forms containing bioadhesive polymers 
and active agents. 
Sr. No. Type of formulations Bioadhesives Active agent 
1 Gel 
Polycarbophil, PVP,   
HPMC 
Chlorhexidine,Flubiprofen 
 
2 Gel Hexadimethrine Triclosan 
3 Ointment Polymethacrylamide Benzyl nicotinate 
1.3.3. Liquids:- 
Liquids have the advantage of being readily distributed throughout the oral 
cavity (eg. Mouth washes) but are not readily retained or targeted to the buccal 
mucosa and would deliver relatively uncontrolled amounts of an active ingredient. 
Viscous liquids may be used to coat buccal surface either as protectants or as drug 
vehicles for delivery to the mucosal surface. Traditionally, pharmaceutically 
acceptable polymers were used to enhance the viscosity of products to aid their 
retention in the oral cavity. Dry mouth is treated with artificial saliva solutions that 
are retained on mucosal surfaces to provide lubrication. 
1.4. Overview of the Oral Mucosa: -          (Johnston T. P., 2005;Surendar Verma .,2011)
 
Buccal region is that part of the mouth bounded anteriorly and laterally by the 
lips and the cheeks, posteriorly and medially by the teeth and/or gums, above and 
below by the reflections of the mucosa from the lips and cheeks to the gums. 
Numerous racemose, mucous or serous glands are present in the submucous tissue of 
the cheeks. The buccal glands are placed between the mucous membrane and 
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buccinator muscle: they are similar in structure to the labial glands, but smaller. 
About five of a larger size than the rest, are placed between the masseter and 
buccinators muscles around the distal extremity of the parotid duct; their ducts open 
in the mouth opposite the last molar tooth. They are called molar glands. Maxillary 
artery supplies blood to buccal mucosa and blood flow is faster and richer 
(2.4ml/min/cm
2
) than that in the sublingual, gingival and palatal regions, thus 
facilitates passive diffusion of drug molecules across the mucosa.  
The oral mucosa is composed of an outermost layer of stratified squamous 
epithelium (Fig. 1.3). Below this lies a basement membrane, a lamina propria 
followed by the submucosa as the innermost layer. The epithelium is similar to 
stratified squamous epithelia found in the rest of the body in that it has a mitotically 
active basal cell layer, advancing through a number of differentiating intermediate 
layers to the superficial layers, where cells are shed from the surface of the 
epithelium. The epithelium of the buccal mucosa is about 40-50 cell layers thick, 
while that of the sublingual epithelium contains somewhat fewer. The epithelial cells 
increase in size and become flatter as they travel from the basal layers to the 
superficial layers. The turnover time for the buccal epithelium has been estimated at 
5-6 days, and this is probably representative of the oral mucosa as a whole. The oral 
mucosal thickness varies depending on the site: the buccal mucosa measures at 500-
800 µm, while the mucosal thickness of the hard and soft palates, the floor of the 
mouth, the ventral tongue and the gingivae measure at about 100-200 µm. The 
composition of the epithelium also varies depending on the site in the oral cavity. The 
mucosa of areas subjected to mechanical stress (the gingivae and hard palate) are 
keratinized similar to the epidermis. The mucosa of the soft palate, the sublingual and 
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the buccal regions are not keratinized. The keratinized epithelia contain neutral lipids 
like ceramides and acylceramides which have been associated with the barrier 
function. These epithelia are relatively impermeable to water. In contrast, non-
keratinized epithelia, such as the floor of the mouth and the buccal epithelia do not 
contain acylceramides and only have small amounts of ceramide. They also contain 
small amounts of neutral but polar lipids, mainly cholesterol sulfate and glucosyl 
ceramides. These epithelia have been found to be considerably more permeable to 
water than keratinized epithelia.        
                  
Fig 1.2      Fig. 1.3 
Fig. 1.2: Section of the buccal epithelium. (a) Superficial layer; (b) basal layer; (c)         
                   Basal membrane and (d) lamina propria (underlying the connective tissue)  
Fig. 1.3: Cross-section of buccal mucosa 
The primary function of buccal epithelium is the protection of the underlying 
tissue. In nonkeratinized regions, lipid-based permeability barriers in the outer 
epithelial layers protect the underlying tissues against fluid loss and entry of 
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potentially harmful environmental agents such as antigens, carcinogens, microbial 
toxins and enzymes from foods and beverages. 
1.4.1. Environment:                                    (Flavia Chiva carvalno et al.,2010) 
The oral cavity is marked by the presence of saliva produced by the salivary 
glands and mucus which is secreted by the major and minor salivary glands as part of 
saliva. The cells of the oral epithelia are surrounded by an intercellular ground 
substance, mucus, the principle components of which are complexes made up of 
proteins and carbohydrates. These complexes may be free of association or some 
maybe attached to certain regions on the cell surfaces. This matrix may actually play a 
role in cell-cell adhesion as well as acting as a lubricant, allowing cells to move 
relative to one another. Along the same lines, the mucus is also believed to play a role 
in bioadhesion of mucoadhesive drug delivery systems. In stratified squamous 
epithelia found elsewhere in the body, mucus is synthesized by specialized mucus 
secreting cells like the goblet cells, however in the oral mucosa; mucus is secreted by 
the major and minor salivary glands as part of saliva. Up to 70% of the total mucin 
found in saliva is contributed by the minor salivary glands. At physiological pH the 
mucus network carries a negative charge (due to the sialic acid and sulfate residues) 
which may play a role in mucoadhesion. At this pH mucus can form a strongly 
cohesive gel structure that will bind to the epithelial cell surface as a gelatinous layer. 
 Role of Mucus:  
 Made up of proteins and carbohydrates 
 Cell-cell adhesion  
 Lubrication  
 Bioadhesion of mucoadhesive drug delivery systems  
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Another feature of the environment of the oral cavity is the presence of saliva 
produced by the salivary glands. Saliva is the protective fluid for all tissues of the oral 
cavity. It protects the soft tissues from abrasion by rough materials and from 
chemicals. It allows for the continuous mineralization of the tooth enamel after 
eruption and helps in demineralization of the enamel in the early stages of dental 
caries. Saliva is an aqueous fluid with 1% organic and inorganic materials. The major 
determinant of the salivary composition is the flow rate which in turn depends upon 
three factors: the time of day, the type of stimulus, and the degree of stimulation. The 
salivary pH ranges from 5.5 to 7 depending on the flow rate. At high flow rates, the 
sodium and bicarbonate concentrations increase leading to an increase in the pH. The 
daily salivary volume is between 0.5 to 2 liters and it is the amount of fluid that is 
available to hydrate oral mucosal dosage forms. A main reason behind the selection of 
hydrophilic polymeric matrices as vehicles for oral transmucosal drug delivery 
systems is this water rich environment of the oral cavity. 
 Role of Saliva:  
 Protective fluid for all tissues of the oral cavity 
 Continuous mineralization / demineralization of the tooth enamel 
 To hydrate oral mucosal dosage forms 
1.4.2. Permeability:
                                        
(Bhalodia R. et al., 2010;Ravi Saurabh et al.,2011) 
     The oral mucosa, in general is a somewhat leaky epithelia intermediate 
between that of the epidermis and intestinal mucosa. It is estimated that the 
permeability of the buccal mucosa is 4-4000 times greater than that of the skin. As 
indicative by the wide range in this reported value, there are considerable differences 
in permeability between different regions of the oral cavity because of the diverse 
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structures and functions of the different oral mucosae. In general, the permeabilities of 
the oral mucosae decrease in the order of sublingual greater than buccal and buccal 
greater than palatal. This rank order is based on the relative thickness and degree of 
keratinization of these tissues with the sublingual mucosa being relatively thin and 
non-keratinized, the buccal thicker and non-keratinized and the palatal intermediate in 
thickness but keratinized.  
It is currently believed that the permeability barrier in the oral mucosa is a 
result of intercellular material derived from the so-called „membrane coating 
granules‟ (MCG). When cells go through differentiation, MCGs start forming and at 
the apical cell surfaces, they fuse with the plasma membrane and their contents are 
discharged into the intercellular spaces at the upper one third of the epithelium. This 
barrier exists in the outermost 200µm of the superficial layer. Permeation studies have 
been performed using a number of very large molecular weight tracers, such as 
horseradish peroxidase and lanthanum nitrate. When applied to the outer surface of 
the epithelium, these tracers penetrate only through outermost layer or two of cells. 
When applied to the submucosal surface, they permeate up to but not into the 
outermost cell layers of the epithelium. According to these results, it seems apparent 
that flattened surface cell layers present the main barrier to permeation, while the 
more isodiametric cell layers are relatively permeable. In both keratinized and non-
keratinized epithelia, the limit of penetration coincided with the level where the 
MCGs could be seen adjacent to the superficial plasma membranes of the epithelial 
cells. Since, the same result was obtained in both keratinized and non-keratinized 
epithelia; keratinization by itself is not expected to play a significant role in the barrier 
function. The components of the MCGs in keratinized and non-keratinized epithelia 
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are different. However, the MCGs of keratinized epithelium are composed of lamellar 
lipid stacks whereas; the non-keratinized epithelium contains MCGs that are non-
lamellar. The MCG lipids of keratinized epithelia include sphingomyelin, 
glucosylceramides, ceramides and other nonpolar lipids. However, for non-
keratinized epithelia, the major MCG lipid components are cholesterol esters, 
cholesterol and glycosphingolipids. Aside from the MCGs, the basement membrane 
may present some resistance to permeation as well, however the outer epithelium is 
still considered to be the rate limiting step to mucosal penetration. The structure of the 
basement membrane is not dense enough to exclude even relatively large molecules. 
1.5. Buccal Absorption:- 
1.5.1. Buccal Routes of Drug Absorption: 
                                                 (Rathbone M.J.et al., 1996;Sachin Shankar et al.,2012)
 
There are two permeation pathways for passive drug transport across the oral 
mucosa: paracellular and transcellular routes. Permeants can use these two routes 
simultaneously, but one route is usually preferred over the other depending on the 
physicochemical properties of the diffusant. Since, the intercellular spaces and 
cytoplasm are hydrophilic in nature; lipophilic compounds would have low 
solubilities in this environment. The cell membrane, however, is rather lipophilic in 
nature and hydrophilic solutes will have difficulty permeating through the cell 
membrane due to a low partition coefficient. Therefore, the intercellular spaces pose 
as the major barrier to permeation of lipophilic compounds and the cell membrane 
acts as the major transport barrier for hydrophilic compounds. Since, the oral 
epithelium is stratified; solute permeation may involve a combination of these two 
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routes. The route that predominates, however, is generally the one that provides the 
least amount of hindrance to passage. 
 Passive diffusion 
 Transcellular or intracellular route (crossing the cell membrane and entering the 
cell) 
 Paracellular or intercellular route (passing between the cells) 
        
 
  
 Transcelluler (Lipoidal pathway) 
 
 Paracelluler (Aqueous pore pathway) 
 
           Fig. 1.4: Mechanism of transmucosal permeation. 
 Carrier mediated transport 
 Endocytosis 
The flux of drug through the membrane under sink condition for paracellular route 
can be written as Eq. (1) 
                          
Where,  
Dp is diffusion coefficient of the permeate in the intercellular spaces 
hp is the path length of the paracellular route 
-------------------------------Equation 1 
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ε is the area fraction of the paracellular route and  
Cd is the donor drug concentration 
Similarly, flux of drug through the membrane under sink condition for transcellular 
route can be written as Eq. (2). 
 
Where,   
Kc is partition coefficient between lipophilic cell membrane and the aqueous phase 
 Dc is the diffusion coefficient of the drug in the transcellular spaces and 
hc is the path length of the transcellular route. 
In very few cases absorption also takes place by the process of endocytosis 
where the drug molecules were engulfed by the cells. It is unlikely that active 
transport processes operate within the oral mucosa; however, it is believed that acidic 
stimulation of the salivary glands with the accompanying vasodilatation facilitates 
absorption and uptake into the circulatory system. The absorption potential of the 
buccal mucosa is influenced by the lipid solubility and molecular weight of the 
diffusant. Absorption of some drugs via the buccal mucosa is found to increase when 
carrier pH is lowered and decreased with an increase of pH. However, the pH 
dependency that is evident in absorption of ionizable compounds reflects their 
partitioning into the epithelial cell membrane, so it is likely that such compounds will 
tend to penetrate transcellularly. Weak acids and weak bases are subjected to pH-
dependent ionization. It is presumed that ionized species penetrate poorly through the 
oral mucosa compared with non-ionized species. An increase in the amount of non-
-------------------------------Equation 2 
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ionized drug is likely to increase the permeability of the drug across an epithelial 
barrier and this may be achieved by a change of pH of the drug delivery system. It has 
been reported that pH has effect on the buccal permeation of drug through oral 
mucosa. The diffusion of drugs across buccal mucosa was not related to their degree 
of ionization as calculated from the Henderson–Hasselbalch equation and thus it is not 
helpful in the prediction of membrane diffusion of weak acidic and basic drugs. 
1.5.2. Buccal Mucosa as a Site for Drug Delivery:    
                                                        (Bhalodia R. et al., 2010;Chinna Reddy P et al.,2011)
 
There are three different categories of drug delivery within the oral cavity (i.e., 
sublingual, buccal, and local drug delivery). Selecting one over another is mainly 
based on anatomical and permeability differences that exist among the various oral 
mucosal sites. The sublingual mucosa is relatively permeable, giving rapid absorption 
and acceptable bioavailabilities of many drugs. It is convenient, accessible and 
generally well accepted. Even though the sublingual mucosa is relatively more 
permeable than the buccal mucosa, it is not suitable for an oral transmucosal delivery 
system. The sublingual region lacks an expanse of smooth muscle or immobile 
mucosa and is constantly washed by a considerable amount of saliva making it 
difficult for device placement. Because of the high permeability and the rich blood 
supply, the sublingual route is capable of producing a rapid onset of action making it 
appropriate for drugs with short delivery period requirements with infrequent dosing 
regimen. Due to two important differences between the sublingual mucosa and the 
buccal mucosa, the latter is a more preferred route for systemic transmucosal drug 
delivery. First difference is in the permeability characteristics of the region, where the 
buccal mucosa is less permeable and is thus not able to give a rapid onset of 
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absorption (i.e., more suitable for a sustained release formulation) and second is that, 
the buccal mucosa has an expanse of smooth muscle and relatively immobile mucosa 
which makes it a more desirable region for retentive systems used for oral 
transmucosal drug delivery. Thus, the buccal mucosa is more fitted for sustained 
delivery applications, delivery of less permeable molecules, and perhaps peptide 
drugs. 
1.5.3 Factors Influencing Buccal Absorption: 
  
                                                                 (Brahmankar D.M. and Jaiswal S.B., 2006) 
Factors that affect the buccal absorption are;  
1) Biphasic solubility of drug :  
The drug should be sufficient lipophillic to cross the oral mucosal barrier and 
sufficiently hydrophilic to dissolute in saliva. Both lipophilicity and hydrophilicity i.e. 
biphasic solubility of the drug is required for buccal/sublingual absorption of drug. 
2) Salivary secretion: 
 For absorption through oral mucosa, the drug must be soluble in the aqueous 
buccal fluid. The absorption also depends on the secretion of saliva. Absorption is 
retarded if the mouth is dry. 
3) pH of saliva: 
The salivary pH ranges between 6 and 7. Increasing the pH of fluid in buccal 
cavity promotes absorption of the weak base but retarded the absorption of weak acid.  
4) Temperature: 
Temperature also affects the buccal absorption of drug to a lesser extent. 
5)  Binding to oral mucosa: 
The systemic availability of the drugs that bind to the oral mucosa is poor.  
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1.6. Experimental Methodology for Buccal Permeation Studies: -
 
                                                                                        
(Chinna Reddy P et al.,2011.,Shojaei A.H., 1998) 
Before a buccal drug delivery system can be formulated, buccal 
absorption/permeation studies must be conducted to determine the feasibility of this 
route of administration for the drug. These studies involve methods that would 
examine In-vitro and/or in-vivo buccal permeation profile and absorption kinetics of 
the drug.  
1.6.1. In-vitro Methods:
  
At the present time, most of the In-vitro studies examining drug transport 
across buccal mucosa have used buccal tissues from animal models. Animals are 
sacrificed immediately before the start of an experiment. Buccal mucosa with 
underlying connective tissue is surgically removed from the oral cavity, the 
connective tissue is then carefully removed and the buccal mucosal membrane is 
isolated. The membranes are then placed and stored in ice-cold (4 °C) buffers (usually 
Krebs buffer) until mounted between side-by-side diffusion cells for the In-vitro 
permeation experiments. The most significant questions concerning the use of animal 
tissues as In-vitro models in this manner are the viability and the integrity of the 
dissected tissue. How well the dissected tissue is preserved is an important issue 
which will directly affect the results and conclusion of the studies. To date, there are 
no standard means by which the viability or the integrity of the dissected tissue can be 
assessed and studied tissue viability by using ATP levels in rabbit buccal mucosa. 
Using ATP levels as an indicator for tissue viability is not necessarily an accurate 
measure. A 50% drop in the tissue ATP concentration during the initial 6 hours of the 
experiment without a corresponding drop in tissue permeability. Despite certain 
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gradual changes, the buccal tissue seems to remain viable for a rather long period of 
time. Therefore, a decrease in ATP levels does not assure a drop in permeability 
characteristics of the tissue. The most meaningful method to assess tissue viability is 
the actual permeation experiment itself, if the drug permeability does not change 
during the time course of the study under the specific experimental conditions of pH 
and temperature, then the tissue is considered viable. 
Buccal cell cultures have also been suggested as useful In-vitro models for 
buccal drug permeation and metabolism. However, to utilize these culture cells for 
buccal drug transport, the number of differentiated cell layers and the lipid 
composition of the barrier layers must be well characterized and controlled. This has 
not yet been achieved with the buccal cell cultures used so far.  
1.6.2. In- vivo Methods:
 
In-vivo methods were first originated by Beckett and Triggs with the so-called 
buccal absorption test. Using this method, the kinetics of drug absorption was 
measured. The methodology involves the swirling of a 25 ml sample of the test 
solution for up to 15 minutes by human volunteers followed by the expulsion of the 
solution. The amount of drug remaining in the expelled volume is then determined in 
order to assess the amount of drug absorbed. The drawbacks of this method include 
salivary dilution of the drug, accidental swallowing of a portion of the sample solution 
and the inability to localize the drug solution within a specific site (buccal, sublingual 
or gingival) of the oral cavity. Various modifications of the buccal absorption test 
have been carried out correcting for salivary dilution and accidental swallowing, but 
these modifications also suffer from the inability of site localization. A feasible 
approach to achieve absorption site localization is to retain the drug on the buccal 
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mucosa using a bioadhesive system. Pharmacokinetic parameters such as 
bioavailability can then be calculated from the plasma concentration vs. time profile. 
Other in-vivo methods include a small perfusion chamber attached to the upper 
lip of anesthetized dogs. The perfusion chamber is attached to the tissue by 
cyanoacrylate cement. The drug solution is circulated through the device for a 
predetermined period of time and sample fractions are then collected from the 
perfusion chamber (to determine the amount of drug remaining in the chamber) and 
blood samples are drawn after 0 and 50 minutes (to determine amount of drug 
absorbed across the mucosa). 
 
1.7. Buccal Drug Delivery and Mucoadhesivity:-
  
                                                                                                   
(Shojaei A.H., 1998; Gattani S. G. et al., 2006)
 
In the development of these buccal drug delivery systems, Residence of the 
device is a key element. The term „mucoadhesive‟ is commonly used for materials 
that bind to the mucin layer of a biological membrane. Mucoadhesive polymers have 
been utilized in many different dosage forms in efforts to achieve systemic delivery of 
drugs through the different mucosa. These dosage forms include Film, patches, tapes, 
films, semisolids and powders. To serve as mucoadhesive polymers, the polymers 
should possess some general physiochemical features such as. 
i.Predominantly anionic hydrophilicity with numerous hydrogen bond-forming groups  
ii. Suitable surface property for wetting mucus/mucosal tissue surfaces and  
iii. Sufficient flexibility to penetrate the mucus network or tissue crevices.  
Following polymers have been tried and tested over the year that includes: 
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Table 1.5: Recent Research on Mucoadhesive Polymers and Its Delivery Systems:  
Bioadhesive Polymer(s) Studied Investigation Objectives 
HPC and CP 
Preferred mucoadhesive strength on CP, HPC, 
and HPC-CP combination 
HPC and CP 
Measured Bioadhesive property using mouse 
peritoneal membrane 
CP, HPC, PVP, CMC 
Studied inter polymer complexation and its 
effects on bioadhesive strength 
CP and HPMC 
Formulation and evaluation of  buccoadhesive 
controlled release delivery systems 
HPC, HEC, PVP, and PVA  
Tested mucosal adhesion on patches with two-
ply laminates with an impermeable backing 
layer and hydrocolloid polymer layer 
HPC and CP 
Used HPC-CP powder mixture as peripheral 
base for strong adhesion and HPC-CP freeze 
dried mixture as core base 
CP, PIP, and PIB 
Used a two roll milling method to prepare a 
new bioadhesive patch formulation 
Xanthum gum and Locust bean gum 
Hydrogel formation by combination of natural 
gums 
Chitosan, HPC, CMC, Pectin, 
Xantham gum, and Polycarbophil 
Evaluate mucoadhesive properties by routinely 
measuring the detachment force form pig 
intestinal mucosa 
Hyaluronic acid benzyl esters, 
Polycarbophil, and HPMC  
Evaluate mucoadhesive properties 
Hydroxyethylcellulose 
Design and synthesis of a bilayer patch 
(polytef-disk) for thyroid gland diagnosis 
Polycarbophil 
Design of a unidirectional buccal patch for oral 
mucosal delivery of peptide drugs 
Poly(acrylic acid) and 
Poly(methacrylic acid) 
Synthesized and evaluated crosslinked 
polymers differing in charge densities and 
hydrophobicity 
Number of Polymers including HPC, 
HPMC, CP, CMC. 
Measurement of bioadhesive potential and to 
derive meaningful information on the structural 
requirement for bioadhesion 
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Poly(acrylic acid-co-acrylamide) 
Adhesion strength to the gastric mucus layer as 
a function of crosslinking agent, degree of 
swelling, and carboxyl group density 
Poly(acrylic acid) 
Effects of PAA molecular weight and 
crosslinking concentration on swelling and 
drug release characteristics 
Poly(acrylic acid-co-methyl 
methacrylate) 
Effects of polymer structural features on 
mucoadhesion 
Poly(acrylic acid-co- butylacrylate) 
Relationships between structure and adhesion 
for mucoadhesive polymers 
HEMA copolymerized with 
Polymeg
®
 (polytetramethylene 
glycol) 
Bioadhesive buccal hydrogel for controlled 
release delivery of buprenorphine 
Cydot
®
 by 3M (bioadhesive 
polymeric blend of CP and PIB) 
Patch system for buccal mucoadhesive drug 
delivery  
Formulation consisting of PVP, CP, 
and cetylpyridinium chloride (as 
stabilizer) 
Device for oramucosal delivery of LHRH - 
device containing a fast release and a slow 
release layer 
CMC, Carbopol 974P, Carbopol EX-
55, Pectin (low viscosity), Chitosan 
chloride,  
Mucoadhesive gels for intraoral delivery 
CMC, CP, Polyethylene oxide, 
Polymethylvinylether/Maleic 
anhydride (PME/MA). 
Buccal mucoadhesive device for controlled 
release anticandidal device - CMC Film 
yielded the highest adhesive force 
HPMC and Polycarbophil (PC) 
Buccal mucoadhesive Film with optimum 
blend ratio of 80:20 PC to HPMC yielding the 
highest force of adhesion 
PVP, Poly(acrylic acid) 
Transmucosal controlled delivery of isosorbide 
dinitrate 
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Poly(acrylic acid-co-poly 
ethyleneglycol) copolymer of acrylic 
acid and poly ethyleneglycol 
monomethylether monomethacryalte 
To enhance the mucoadhesive properties of 
PAA for buccal mucoadhesive drug delivery 
Poly acrylic acid and poly ethylene 
glycol 
To enhance mucoadhesive properties of PAA 
by interpolymer complexation through 
template polymerization 
Drum dried waxy maize starch 
(DDWM), Carbopol 974P, and 
sodium stearylfumarate 
Bioadhesive erodible buccal film for 
progesterone delivery 
 
1.8. Buccal Adhesive Polymers: -              (Chien Y. W., 2009; Johnston T. P. et al., 2005)
 
Polymer is a generic term used to describe a very long molecule consisting of 
structural units and repeating units connected by covalent chemical bonds. The key 
feature that distinguishes polymers from other molecules is the repetition of many 
identical, similar, or complementary molecular subunits in these chains. These 
subunits, the monomers, are small molecules of low to moderate molecular weight 
and are linked to each other during a chemical reaction called polymerization. Instead 
of being identical, similar monomers can have varying chemical substituents. The 
differences between monomers can affect properties such as solubility, flexibility and 
strength. The term buccal adhesive polymer covers a large, diverse group of 
molecules, including substances from natural origin to biodegradable grafted 
copolymers and thiolated polymers. Bioadhesive formulations use polymers as the 
adhesive component. These formulations are often water soluble and when in a dry 
form attract water from the biological surface and this water transfer leads to a strong 
interaction. These polymers also form viscous liquids when hydrated with water that 
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increases their retention time over mucosal surfaces and may lead to adhesive 
interactions. Bioadhesive polymers should possess certain physicochemical features 
including hydrophilicity, numerous hydrogen bond-forming groups, flexibility for 
interpenetration with mucus, epithelial tissue and visco-elastic properties. 
1.8.1. Ideal Characteristics: 
                                    (Saroj Kumar R. and Bala P., 2010; Bandyopadhyay A. K., 2008) 
 Polymer and its degradation products should be non-toxic, non-irritant and 
free from leachable impurities.  
 It should have good spreadability, wetting and swelling properties, solubility 
and biodegradability.  
 The pH should be biocompatible and should possess good viscoelastic 
properties.  
 It should adhere quickly to buccal mucosa and should possess sufficient 
mechanical strength.  
 It should possess peel, tensile and shear strengths at the bioadhesive range.  
 Polymer must be easily available and its cost should not be high.  
 It should show bioadhesive properties in both dry and liquid state. 
 It should demonstrate local enzyme inhibition and penetration enhancement 
properties.  
 It should demonstrate acceptable shelf life.  
 It should have optimum molecular weight.  
 It should possess active groups responsible for adhesion.  
 It should have required spatial conformation.  
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 It should be sufficiently cross-linked but not to the degree of suppression of 
bond forming groups.  
 It should not aid in development of secondary infections such as dental caries. 
 
1.9. Commercial Buccal Adhesive Drug Delivery Systems:
 
    
                                                                                                (Sudhakar Y. et al., 2006) 
Recent reports suggested that the market share of buccal adhesive drug 
delivery systems are increasing in the American and European market with the steady 
growth rate of above 10%. Some of the commercially available buccal adhesive 
formulations are listed in Table 1.6. 
Table 1.6:  Buccal formulations marketed or in clinical trial intended for both 
mucosal (local), or transmucosal (systemic) Administration 
 
 
Sr. 
N0. 
Brand 
Name 
Active agent Effect 
Functional 
agent 
Company 
1 
Aphtach 
(Tab) 
Triamcinolone 
acetonide 
Local 
(mouth) 
 
HPC, 
Polyacrylic 
acid 
Teijin Ltd 
 
2 
Buccastem 
(Tab) 
Prochlorperazine Systemic 
Xanthan 
gum, 
Povidone 
Reckitt 
Benkiser Plc 
3 
Oralin-
Generex 
(Soln) 
Insulin Systemic Unknown 
Generex 
Biotechnoloy 
 
4 
Lauriad  
       (Tab) 
Miconazole 
Local (mouth 
& 
Oropharyx) 
Unknown 
BioAlliance 
Pharma 
 
5 
Striant SR 
(Tab) 
Testosterone Systemic 
HPMC, 
Carbomer 
934 P 
Ardama 
Bioscience 
Ltd. 
 
  
 
 
 
LITERATURE 
SURVEY 
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2. LITERATURE SURVEY 
 
2.1. Literature Review:- 
Recent Advancements in Bucccoadhesive Drug Delivery Systems: 
1) Siddarth S. D.  and Upendra K., (2010) formulated a buccal dosage form. A 
number of buccal mucoadhesive patches of Felodipine were prepared by 
casting method using polyvinyl pyrrolidone (PVP) and polyvinyl alcohol 
(PVA) as polymer. Glycerin and propylene glycol were used as plasticizers, 
Stability study revealed that the percent drug content decreased in various 
patches was ranging from 1.15 to 1.90. 
2) Saroj Kumar R. and Bala P., (2010) had described, of the various routes of 
drug delivery; the oral route is often preferred by the patient. However, peroral 
administration of drugs has disadvantages such as hepatic first-pass metabolism 
and enzymatic degradation within the gastrointestinal tract which constitutes a 
hindrance to oral administration of certain classes of drugs, especially peptides 
and proteins. This review describes various bio/mucoadhesive polymers used in 
transmucosal drug delivery. 
3) Subash P. et al., (2010) had formulated Buccal patches of Isoxsuprine 
Hydrochloride, a potent and long acting vasodilator and uterine suppressant , 
by using Hydroxyl propyl methyl cellulose(HPMC), Polyvinyl pyrolidone K-50 
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(PVP K-50) and Hydroxyl ethyl cellulose (HEC). Higuchis plot studies 
revealed that the predominant mechanism of drug release was diffusion. 
4) Navneet G. et al., (2010) had prepared  Mucoadhesive  Tablets  of  Salbutamol  
Sulphate  by  non  aqueous  granulation  of  polymers  HPMC  K‐4M  
(Hydroxypropyl  Methyl Cellulose)  & EC (Ethyl Cellulose) in different ratios 
1:1. 1:2 & 2:1. In vitro bioadhesive strength studies showed that Film 
containing more HPMC K‐4M were great bioadhesive in nature. The maximum 
in‐vitro release observed in formulation HE‐1. (1:1 ratio) and the kinetics 
studies shows that release follows peppas model. 
5) Asha S. J. et al., (2010) studied mucoadhesive bilayer buccal tablets of 
Atorvastatin Calcium using the bioadhesive polymers Carbopol 934P (CP), 
Sodium CMC, Hydroxy ethyl cellulose (HEC) and Sodium alginate (Na-
alginate) along with ethyl cellulose as an impermeable backing layer. Film 
containing CP and Na-CMC in the ratio of 3:2 (F2) had the maximum 
percentage of in-vitro drug release without disintegration in 6 h. 
6) Hirlekar R. S., (2009) prepared Carvedilol buccal tablet, Drug-Methyl-β- 
cyclodextrin complex was prepared by kneading method and characterized by 
Fourier Transformation Infrared spectroscopy, Differential Scanning 
Calorimetry and powder X-Ray Diffractometry studies.  
7) Rajesh S. P. and Poddar S. S., (2009) had prepared and evaluated of 
mucoadhesive buccal patches for the controlled systemic delivery of 
Salbutamol Sulphate to avoid first pass hepatic metabolism. The developed 
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patches were evaluated for the physicochemical, mechanical and drug release 
characteristics. The patches showed desired mechanical and physicochemical 
properties to withstand environment of oral cavity.  
8) Aleksandra M. S. et al., (2008) had determine the possibility of transmucosal 
iontophoretic delivery of cationic drug and to investigate ex vivo Galantamine 
HBr and Naltrexone Hydrochloride administration via buccal mucosa by 
applying the iontophoresis and to define of initial donor drug concentration (in 
the presence and without of competitive cations) and current density influences 
on drug flux. 
9) Thimmasetty J. et al., (2008) had prepared Carvedilol patches using HPMC, 
carbopol 934, eudragit RS 100, and ethyl cellulose. The patches were evaluated 
for their thickness uniformity, folding endurance, weight uniformity, content 
uniformity, swelling behaviour, tensile strength, and surface pH. In vitro 
release studies were conducted for carvedilol-loaded patches. In vivo drug 
release studies in rabbits showed 90.85% of drug release from HPMC-carbopol 
patch while it was 74.63 to 88.02% within 90 min in human volunteers. Good 
correlation among in vitro release and in vivo release of carvedilol was 
observed. 
10) Akpa P. A. et al., (2008)   studied the buccoadhesive and in vitro release 
properties of patches formulated with ethyl cellulose (EC) and hydroxyl propyl 
methyl cellulose (HPMC) interpolymer complexes of different ratios. The 
result of the study indicated that1:2 ratios of EC and HPMC gave the highest 
buccoadhesive strength. 
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11) Belgamwar V. S. et al., (2007) prepared mucoadhesive multiparticulate system 
following ionic gelatin technique for oral drug delivery. Microspheres so 
prepared showed encapsulation efficiency ranging between 60% - 70% and had 
a mean particle size 400- 700µm as determined by optical microscopy. 
12) Madhusudan R. Y. et al., (2007) had developed a buccal patch for systemic 
administration of Carvedilol in the oral cavity has been using two different 
mucoadhesive polymers. The results indicate that suitable bioadhesive buccal 
patches with desired permeability could be prepared. . The bioavailability of 
carvedilol from buccal patches has increased 2.29 folds when compared to that 
of oral solution. The formulation AC5 (HPMC E 15) shows 84.85 + 0.089% 
release and 38.69 + 6.61% permeated through porcine buccal membrane in 4 
hr. 
13) Ramana M. V. et al., (2007) fabricated mucoadhesive buccal tablet of 
Metaprolol Tartarate with objective of avoiding first pass metabolism and 
providing duration of action. The best mucoadhesive performance and in-vitro 
drug release profile were exhibited by the Film containing hydroxyl ethyl 
cellulose and carbopol-934 in ratio 1:2. 
14) Nakhat P. D. et al., (2007) had developed buccoadhesive bilayered tablet 
comprising of drug containing bioadhesive layer and drug free backing layer to 
release the drug for extended period of time with reduction in dosing 
frequency. Carboplo-934P and methocel K4M in the ratio of 1:1 could be used 
to design effective and stable buccoadhesive Film of Terbutaline Sulphate. 
15) Nakhat P. D. et al., (2007) had formulated buccoadhesive tablet of 
Promethazine Hydrochloride to circumvent the first pass effect and to improve 
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its oral bioavailability with reduction in dosing frequency. All the formulations 
followed non- Fickian release mechanism. The optimized formulation F12 
showed stability for the span of 6 months at 40±2° and 75±5% RH. 
16) Pramodkumar T. M. and Shivakumar H.G., (2006)  prepared 
Buccoadhesive core-in-cup (BCC) systems of Terbutaline Sulphate by the 
direct compression method with polymers, like carbopols and hydroxy propyl 
methyl cellulose 4KM (HPMC 4KM) in ratios of 1: 0, 1: 1, 1: 2 and 0: 1. 
Buccoadhesive ﬁlms were prepared by solvent evaporation using chitosan, 
HPMCK4M and HPMCP. Buccoadhesive core-in-cup systems and ﬁlms of 
terbutaline sulphate can be developed as potential controlled release 
formulations for the treatment of bronchial asthma. 
17) Peppas N. A. et al., (2006) had developed novel acrylic based polymers that 
can be used as a mucoadhesive delivery system. The effects of different PEG-
tethered structures on Residencewere studied using a tensionetric testing and 
the work of adhesion was calculated. 
18) Prachiti P. V. et al., (2006) provides an overview of buccal drug delivery 
system which includes various dosage forms like patch, film, film, 
microspheres and their evaluation tests and also given brief review of patents 
on buccal drug delivery system. 
19) Cafaaggi S. et al., (2005) had prepared and evaluated a matrix for buccal drug 
delivery composed of a Chitosan salt and poloxamer 407. The matrix 
composed of chitosan lactate and poloxamer 407 showed the best 
characteristics for buccal administration. 
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20) Satyabratha B. et al., (2005) designed and evaluated the controlled release of 
mucoadhesive buccal tablet of Captopril with a goal to increase the 
bioavailability, reduced dosing frequency and improve patient compliance. The 
results indicate that the mucoadhesive buccal Film of Captopril may be a good 
choice to bypass the extensive hepatic first pass metabolism with an 
improvement in the bioavailability. 
21) Johnston T. P. et al., (2005) highlighted the use of mucoadhesive polymers in 
buccal drug delivery. Starting with a review of the oral mucosa, mechanism of 
drug permeation, and characteristics of desired polymers, it also covered the 
theories behind the adhesion of bioadhesive polymers to the mucosal 
epithelium.   
22) Ayyappan T. and Kasture P.V., (2005) had developed and evaluated a 
buccoadhesive Ondansetron Hydrochloride tablet formulation using various 
mucoadhesive polymers in varying ratios. From this study, they concluded that 
tablet prepared from Carbopol 934P and Sodium carboxy methyl cellulose in a 
ratio of 1:4 exhibited the maximum drug release in 8 hr as compared to other 
polymeric ratios. 
23) Akbari J. et al., (2004) reported the effects of fillers on the release of 
Propranolol Hydrochloride. The result indicated that the presence of fillers 
increases dissolution rate of the drug. The release data also showed that the 
effect of lactose on the dissolution rate was greater than the DCP. 
24) Park C. and Munday D. L., (2002) prepared and evaluated to determine the 
suitability of the formulation as a nicotine replacement product to aid in 
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smoking cessation. A combination of 20% w/w Carbopol 934 and 20% w/w 
HPC was thus found to provide suitable adhesion and controlled drug release. 
25) Johnston T. P. et al., (1999) had evaluated the gum from Hakea Gibbosa as a 
sustained release and mucoadhesive component in buccal Film following their 
application to the buccal mucosa of rabbits. The mucoadhesive buccal Film 
evaluated represent an improved transbuccal delivery system for conventional 
drug substances. 
26) Javed A. et al., (1999) prepared the buccoadhesive carriers of Triamcinolone 
Acetomide using different bioadhesive polymers in the different ratio in order 
to study effect on drug release and bioadhesion. The formulation containing 8 
mg of triamcinolone acetomide, 2 magnesium stearate along with carbopol-
934P and sodium carboxy methyl cellulose in the ratio of 1:4 was found to 
release the drug for period of 8 hours without getting dislodged. 
27) Shojaei A. H., (1998) described that, within the oral mucosal cavity, the buccal 
region offers an attractive route of administration for systemic drug delivery. 
The mucosa has a rich blood supply and it is relatively permeable. It is the 
objective of this article to review buccal drug delivery by discussing the 
structure and environment of the oral mucosa and the experimental methods 
used in assessing buccal drug permeation/absorption. Buccal dosage forms will 
also be reviewed with an emphasis on bioadhesive polymeric based delivery 
systems. 
28) Agarwal S. P. et al., (1996) had prepared buccoadhesive erodible Film for 
local delivery of Clotrimazole to the oral cavity were developed using different 
bioadhesive polymers along with suitable excipients. The in vitro adhesion time 
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and release characteristics were found to be function of the type of polymer and 
also the total composition of the Film. 
29) Hung S. C. and Ahmad M. M., (1995) developed a new and simple dissolution 
apparatus which is capable of evaluating the release of drug and bioadhesive 
properties of buccal Film. Film with higher concentrations of HPMC provide 
more prolonged release of drug.  However they can be dislodging from the 
membrane more easily. 
30) Suraj P. A. et al., (1995) had developed mucoadhesive buccal drug delivery 
system, multilayered Film of Diltiazem Hydrochloride were prepared which 
gave an in vitro drug release of 86.00%. In-situ testing was done using bovine 
cheek pouch membrane in a Franz diffusion cell. 
  
 
 
 
 
 
 
DRUG 
AND 
POLYMER PROFILE 
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 2.2.  DRUG PROFILE:-
 
 (http:// www.google.com, drug bank; http://www.rxlist.; 
Anthony C. et al., 2004; Tripathi K.D., 2004; PoptaniSanjay D .et al.,2012)  
METOPROLOL TARTRATE:  
Chemical structure: 
 
Chemical name : (±)-1-(Isopropylamino)-3-[p-(2-methoxyethyl)phenoxy]-2- 
                                Propanol L-(+)-tartrate 
Molecular Weight: 684.8 
Molecular Formula: (C15H25NO3)2 C4H6O6 
Category: 
Anti adrenergic agents, adrenergic beta-Antagonists, Anti-Arrhythmia Agents, 
Antihypertensive Agents, and  Sympatholytics. 
Dose: 
 Conventional dose:-  Initially 50 to 100 mg daily in a single or divided doses may 
increases weekly to 400 mg daily. 
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 Maintenance dose:- 100 to 200 mg daily 
 Extended release preparation:- 25 to 100 mg once daily. 
Description: Metoprolol tartrate USP is a white, practically odorless. 
Solubility: 
It is very soluble in water and 0.1 N HCl freely soluble in methylene chloride, in 
chloroform,and in alcohol; slightly soluble in acetone; and insoluble in ether. 
Melting Point: 120 to 122° C (Succinate 136-138 °C) 
Storage: Preserve in well-closed containers, at temperature not exceeding 25
o
 C. 
Mechanism of action: 
Metoprolol competes with adrenergic neurotransmitters such as catecholamines for 
binding at beta(1)-adrenergic receptors in the heart and vascular smooth muscle. 
Beta(1)-receptor blockade results in a decrease in heart rate, cardiac output, blood 
pressure. 
Pharmacology: 
Metoprolol, a competitive, beta1-selective (cardioselective) adrenergic antagonist, is 
similar to atenolol in its moderate lipid solubility, lack of intrinsic sympathomimetic 
activity (ISA), and weak membrane stabilizing activity (MSA). 
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Pharmacokinetic profile: 
 Metoprolol tartrate is absorbed rapid and completely from upper part of GIT. 
 PKa  : 9.7. 
 Partition coefficient  : 1.9 (Octanol / 0.1 N HCl) 
 Vd  : 4L/ Kg. 
 Half-life  : 3 to 4 hrs. 
 Body Clearance  : 13 ml/min/kg. 
 Protein Binding  : 11%. 
 Oral Bioavailability  : 40 to 50 %. 
Therapeutic uses: 
 Hypertension ,  
 Angina pectoris, 
 Cardiac arrhythmias, 
 Myocardial infraction, 
 Migraine prophylaxis and Hyperthyroidism. 
Drug interactions: 
 Beta-blocker and Calcium channel blocker have additive effect on the cardiac 
conducting system. 
 Catecholamine depleting drug like Reserpine have additive effect with beta-
blocker. 
 Phenytoin, rifampicin, and phenobarbital induce hepatic biotransformation of 
enzymes and may decrease plasma concentration of beta blockers,  Cimetidine 
and hydralazine may increase the bioavailability of agents such as propranolol 
and metoprolol by affecting hepatic blood flow. 
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Contraindication: 
Hypertension and Angina: Extended release metoprolol tartrate is contraindicated in 
sinus bradycardia, heart block greater than first degree, cardiogenic shock. 
Toxicity: 
LD50=5500 mg/kg (orally in rats), toxic effects include bradycardia, hypotension, 
bronchospasm, and cardiac failure. LD50=2090 mg/kg (orally in mice). 
Dosage forms: 
Table 2.1. Dosage forms and routes of administration of Metoprolol 
             Form Route 
Liquid Intravenous 
Solution Intravenous 
Film Oral 
Film extended release Oral 
Marketed preparations: 
Beloc, Betaloc, Lopresor, Lopresoretic, Lopressor, Lopressor, HCT,Metroprolol, 
Prelis, Selo-Zok, Seloken, Selopral, Toprol, Toprol- XL 
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2.3. POLYMERS PROFILES: -
       
(Raymond C. Rowe, 2003)  
2.3.1. CARBOMER   (CARBOPOL) 
1. Nonproprietary Names: 
 BP: Carbomers 
PhEur: Carbomera 
USPNF: Carbomer 
2. Synonyms: 
Acritamer; acrylic acid polymer; Carbopol; carboxy polymethylene, polyacrylic acid; 
carboxyvinyl polymer; Pemulen; Ultrez. 
3. Chemical Name and CAS Registry Number: Carbomer [9003-01-4] 
4. Molecular Weight: 86,000 
5. Structural Formula: 
      
Carbomer polymers are formed from repeating units of acrylic acid. The 
monomer unit is shown above. The polymer chains are crosslinked with allyl sucrose 
or allyl pentaerythritol. 
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6. Functional Category: 
Bioadhesive; emulsifying agent; release-modifying agent; suspending agent; 
film binder; viscosity-increasing agent. 
7. Applications in Pharmaceutical Formulation or Technology: 
Carbomers are mainly used in liquid or semisolid pharmaceutical formulations 
as suspending or viscosity-increasing agents. Formulations include creams, gels, and 
ointments for use in ophthalmic, rectal, and topical preparations. Carbomer grades, 
even with a low residual benzene content, such as carbomer 934P, are no longer 
included in the PhEur 2005. Carbomer having low residuals only of ethyl acetate, 
such as carbomer 971P or 974P, may be used in oral preparations, in suspensions, 
Film, or sustained release film formulations.In film formulations, carbomers are used 
as dry or wet binders and as a rate controlling excipient. In wet granulation processes, 
water or an alcohol–water blend is used as the granulating fluid. Anhydrous organic 
solvents have also been used, with the inclusion of a polymeric binder. The tackiness 
of the wet mass can be reduced with the addition of certain cationic species to the 
granulating fluid or, in the case of water, with talc in the formulation.  
         Uses                                                 Concentrations (%) 
Emulsifying agent                                     0.1–0.5 
Gelling agent                                             0.5–2.0 
Suspending agent                                      0.5–1.0 
Film binder                                             5.0–10.0 
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8. Description: 
Carbomers are white-colored, „fluffy‟, acidic, hygroscopic powders with a 
slight characteristic odor. 
9. Typical Properties:- 
Acidity/alkalinity       :          pH = 2.7–3.5 for a 0.5% w/v aqueous dispersion; 
                        pH = 2.5–3.0 for a 1% w/v aqueous dispersion. 
Density (bulk)           :           1.76–2.08 g/cm3 
Density (tapped)       :           1.4 g/cm3 
Melting point            :           Decomposition occurs within 50 minutes at 260°C.  
Moisture content:  
            Normal water content is up to 2% w/w. However, carbomers are hygroscopic 
and typical equilibrium moisture content at 25°C and 50% relative humidity is 8–10% 
w/w. The moisture content of a carbomer does not affect its thickening efficiency, but 
an increase in the moisture content makes the carbomer more difficult to handle 
because it is less readily dispersed. 
Solubility:  
           Soluble in water and, after neutralization, in ethanol (95%) and glycerin. 
Although they are described as „soluble‟, carbomers do not dissolve but merely swell 
to a remarkable extent, since they are three-dimensionally crosslinked microgels. 
Furthermore, the pharmacopeial specifications are unclear, in that neutralization with 
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long-chain aliphatic amines or ethoxylated long-chain amines is required for 
swellability in ethanol, and with water-soluble amines for swellability in glycerin. 
Viscosity (dynamic):  
           Carbomers disperse in water to form acidic colloidal dispersions of low 
viscosity that, when neutralized, produce highly viscous gels. Carbomer powders 
should first be dispersed into vigorously stirred water, taking care to avoid the 
formation of indispersible lumps, thenneutralized by the addition of a base. The 
Carbopol ETD and Ultrez 10 series of carbomerswas introduced to overcome some of 
the problems of dispersing the powder into aqueous solvents. These carbomer resins 
wet quickly yet hydrate slowly, while possessing a lower unneutralized dispersion 
viscosity.  
 
10. Stability and Storage Conditions: 
Carbomers are stable, hygroscopic materials that may be heated at 
temperatures below 104°C for up to 2 hours without affecting their thickening 
efficiency. However, exposure to excessive temperatures can result in discoloration 
and reduced stability.  
 
 
 
 
Novel Buccoadhesive film of Metoprolol tartrate                                     Drug and Polymer Profile  
 
Adhiparasakthi College of Pharmacy, Melmaruvathur.                                                                   49 
 
 
2.3.2. HYPROMELLOSE (HYDROXYPROPYL METHYLCELLULOSE) 
1. Nonproprietary Names: 
BP: Hypromellose                    
JP: Hydroxypropylmethylcellulose                    
PhEur: Hypromellosum 
USP: Hypromellose 
2. Synonyms: 
Benecel MHPC; E464; hydroxypropyl methylcellulose; HPMC; Methocel; 
methylcellulose propylene glycol ether; methyl hydroxypropylcellulose; Metolose; 
Tylopur. 
3. Chemical Name and CAS Registry Number: 
Cellulose hydroxypropyl methyl ether [9004-65-3] 
4. Molecular Weight: 
Molecular weight is approximately 10 000–1 500 000.  
5. Structural Formula: 
 
Where R is H, CH3, or CH3CH (OH) CH2 
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6. Functional Category: 
Coating agent; film-former; rate-controlling polymer for sustained release; 
stabilizing agent;suspending agent; film binder; viscosity-increasing agent. 
7. Applications in Pharmaceutical Formulation or Technology: 
In oral products, hypromellose is primarily used as a film binder, in film-
coating, and as matrix for use in extended-release film formulations.  Concentrations 
between 2% and 5% w/w may be used as a binder in either wet- or dry-granulation 
processes. High-viscosity grades may be used to retard the release of drugs from a 
matrix at levels of 10–80% w/w in Film and capsules. Depending upon the viscosity 
grade, concentrations of 2–20% w/w are used for film-forming solutions to film-coat 
Film. Hypromellose at concentrations between 0.45–1.0% w/w may be added as a 
thickening agent to vehicles for eye drops and artificial tear solutions.  
8. Description: 
Hypromellose is an odorless and tasteless, white or creamy-white fibrous or 
granular powder. 
9. Typical Properties:- 
Acidity/alkalinity                :         pH = 5.5–8.0 for a 1% w/w aqueous solution. 
Ash                                        :      1.5–3.0%, depending upon the grade and viscosity. 
Autoignition temperature   :          360°C 
Density (bulk)                       :         0.341 g/cm3 
Density (tapped)                   :         0.557 g/cm3 
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Density (true)                           :          1.326 g/cm3 
Melting point                           :           Browns at 190–200°C; chars at 225–250°C. 
                                                               Glass transition temperature is 170–180°C. 
Moisture content:  
          Hypromellose absorbs moisture from the atmosphere; the amount of water 
absorbed depends upon the initial moisture content and the temperature and relative 
humidity of the surrounding air.  
Solubility:  
            Soluble in cold water, forming a viscous colloidal solution; practically 
insoluble in chloroform, ethanol (95%), and ether, but soluble in mixtures of ethanol 
and dichloromethane, mixtures of methanol and dichloromethane, and mixtures of 
water and alcohol. Certain grades of hypromellose are soluble in aqueous acetone 
solutions, mixtures of dichloromethane and propan-2-ol, and other organic solvents.  
Viscosity (dynamic):  
            A wide range of viscosity types are commercially available. Aqueous 
solutions are most commonly prepared, although hypromellose may also be dissolved 
in aqueous alcohols such as ethanol and propane-2-ol provided the alcohol content is 
less than 50% w/w.  
Typical viscosity values for 2% (w/v) aqueous solutions of Methocel (Dow Chemical 
Co.). Viscosities measured at 20°C. 
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10. Stability and Storage Conditions: 
Hypromellose powder is a stable material, although it is hygroscopic after 
drying. Solutions are stable at pH 3–11. Increasing temperature reduces the viscosity 
of solutions. Hypromellose undergoes a reversible sol–gel transformation upon 
heating and cooling, respectively. The gel point is 50–90°C, depending upon the 
grade and concentration of material.  
 
11. Incompatibilities: 
Hypromellose is incompatible with some oxidizing agents. Since it is 
nonionic, hypromellose will not complex with metallic salts or ionic organics to form 
insoluble precipitates. 
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Metoprolol tartrate is a selective β-1 adrenergic antagonist used in the 
treatment of the cardiovascular system, especially Hypertension. This drug, with 12% 
oral bioavailability and having half-life of 3 to 4 hours, is readily and completely 
absorbed from the gastro intestinal tract but is subjected to considerable first-pass 
metabolism. It is a “class- ” drug according to Biopharmaceutics classification system 
(BCS), possessing both high solubility and high permeability absorption 
characteristics. It has a short elimination half-life and rapidly absorbed in 
gastrointestinal tract. If it is formulated by conventional tablets requires multiple daily 
administration (3-4 times daily) with resulting in convenience to the patient and the 
possibility of reduced compliance with prescribed therapy. 
These physico-chemical properties of metoprolol tartrate make its suitable 
candidate for administration by buccal route. 
One of the significant approaches in the modern drug delivery systems is to 
target the drug in particular part of the body. Mucosal surface has attracted attention 
of scientific community in the living body; mucosal surfaces are available in the oral 
cavity especially to the buccal region. 
 The present study focused on the delivery of drug via buccal mucosa. Drug or 
the dosage forms have to exhibit mucoadhesive properties to remain static at the site 
of application. Oral mucosa is robust and shows short recovery time after stress or 
damage. Mucoadhesive dosage forms are readily localized in the region and 
prolonged resistance time and absorption of the drug at the site of administration. 
3. AIM AND OBJECTIVES 
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These dosage forms facilitate intimate contact of the formulation with the underlying 
absorption surface. 
Buccal drug delivery has been considered as an alternative to oral dosing for 
compound subjected to degradation in the GIT or to undergo extensive first pass 
metabolism. Buccal drug delivery offers a safer mode of utilization, since drug 
absorption can be promptly terminated in case of toxicity by removing the dosage 
form from the buccal cavity. 
An attempt was taken to develop the buccoadhesive Film with this drug to 
minimize the fluctuations in blood concentration by avoiding first pass effect, 
decreasing the risk of side effects and show uniform pharmacological response. 
            The aim of present work was to formulate and evaluate buccoadhesive Film of 
Metoprolol tartrate containing 50 mg of drug, using a mucoadhesive polymer with the 
help of solvent casting method   in order to the release  for the period of  8 hours.  
This type of formulation will ensure minimum fluctuations in the plasma drug 
concentration and reduced dosing frequency which in turn will result into improved 
patient compliance.  
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4. PLAN OF WORK 
 
 LITERATURE SURVEY  
 SELECTION OF DRUG  AND POLYMERS  
 PROCUREMENT OF DRUG AND POLYMERS  
 EXPERIMENTAL WORK 
 Preformulation Study 
Identification of Drug  
 Organoleptic Properties 
 Determination of Melting Point     
 Solubility Study 
 FTIR 
 UV Spectrophotometric Study 
 Assay of Metoprolol tartrate 
 Differential Scanning Calorimetry  (DSC) 
 Formulation Design of 23 full factorial design 
 Formulation of Buccoadhesive film 
1. Backing layer 
2. Buccoadhesive layer containing drug  
 Evaluation of Buccoadhesive film  
 Appearance  
 Film thickness & determination of weight of film 
 Folding endurance 
 Swelling index 
 Surface pH  
 Content uniformity 
 Ex Vivo Buccoadhesive Strength 
 Ex Vivo Residence Time 
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 In Vitro Drug release Study 
 In Vitro Buccal permeation study 
 Histopathological studies 
 Kinetics modeling of Drug Release Profile 
 Statistical Analysis of response by Design Expert software 
 Stability Study 
 RESULTS AND DISCUSSION 
 SUMMARY AND CONCLUSION 
 FUTURE PROSPECTS 
 BIBLIOGRAPHY 
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5. MATERIALS AND EQUIPMENTS 
 
5.1.MATERIALS USED 
 
Table 5.1: List of Drug and Polymers with source 
 
Sr.No. Ingredients Supplier 
1 Metoprolol tartrate Madras Pharmaceuticals Pvt 
Ltd,Chennai. 
2 Carbopol-934P Loba Chemie, Mumbai. 
3 Hydroxy Propyl Methyl 
Cellulose   K4M 
Loba Chemie, Mumbai. 
4 Di Methyl Sulphoxide Loba Chemie, Mumbai. 
5 Ethyl Cellulose Loba Chemie, Mumbai. 
6 Di Butyl Pthalate Loba Chemie, Mumbai. 
7 Ethanol Loba Chemie, Mumbai. 
8 Propylene Glycol Loba Chemie, Mumbai. 
9 Potassium di Hydrogen 
phosphate 
Loba Chemie, Mumbai. 
10 Sodium hydroxide Loba Chemie, Mumbai. 
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5.2. EQUIPMENTS USED: 
 
Table 5.2: List of Equipments with model/make 
 
Sl. 
No. 
Name of the Instruments Make Model 
1  Electronic Balance Shimadzu, Japan BL- 200H. 
2 UV-Visible Spectrophotometer Shimadzu, Japan 1700 
3 FTIR Spectrophotometer Perkin elmer-Pharmaspec-1 ---- 
4 
USP, Type II Dissolution Test 
Apparatus 
Veego scientifics,  Mumbai 
VDA – 
8DR. 
5 Digital pH Meter Elico scientifics,  Mumbai L1610 
6 Hot air oven 
Prescision scientific co., 
Chennai 
P-1401 
7 Vernier Calipers Indolabs, Chennai --- 
8 Humidity Chamber Labtech, Ambala ---- 
9 Melting Point Test Apparatus 
Prescision scientific co., 
Chennai 
---- 
10   Physical Balance Fabricated assembly in lab ---- 
11 Differential Scanning Calorimeter Shimadzu Japan Q20V24.4 
12 Magnetic Stirrer Labtech, Ambala ---- 
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6. PRE-FORMULATION STUDY 
6.1. Identification of Drug:-  (Anthony C. et al., 2004; Indian Pharmacopoeia, 2007) 
6.1.1. Organoleptic Properties: 
The colour, odour and taste of the drug were recorded using descriptive 
terminology. 
6.1.2. Melting Point:
 
Melting point of the drug was determined by capillary tube method. 
6.1.3. Solubility Study:
 
It is important to know about solubility characteristic of a drug in aqueous 
system. Since they must possess some limited aqueous solubility to elicit a therapeutic 
response. The solubility of drug was recorded by using various descriptive 
terminology specified in Indian Pharmacopoeia, 2007. 
6.1.4. UV Spectrophotometric Study: 
 
The absorption maximum of the standard solution was scanned between 200-
400 nm regions on UV-Visible Spectrophotometer. The absorption maximum 
obtained with the substance being examined corresponds in position and relative 
intensity to those in the reference spectrum. 
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Preparation of Standard Curve of Metoprolol tartrate: 
 Preparation of  Solutions: 
Preparation of Phosphate Buffer pH 6.8: Phosphate buffers pH 6.8 was 
prepared according to I.P. A quantity of 50.0 ml of 0.2 M potassium dihydrogen 
phosphate in a 200 ml volumetric flask and add 22.4 ml of 0.2 M sodium hydroxide 
and then add water to volume. 
Stock solution of Metoprolol tartrate was prepared by phosphate buffer pH 
6.8. Accurately weighed 100 mg of Metoprolol tartrate was dissolved in little quantity 
of phosphate buffer pH 6.8 and volume was adjusted to 100 ml with the same to 
prepare standard solution having concentration of 100 µg/ ml.  
 Procedure:  
From the stock solution, aliquots of 1, 2,3,4,5 and 6 ml were transferred to 10 
ml volumetric flasks and final volume was made to 10 ml with phosphate buffer pH 
6.8. Absorbance values of these solutions were measured against blank at 274.5 nm 
using UV-Visible Spectrophotometer.  
6.1.5. Percentage Purity of Drug:
 
Accurately weighed 10 mg of Metoprolol tartrate was dissolved in little 
quantity of phosphate buffer pH 6.8 and volume was adjusted to 100 ml with the same 
to prepare standard solution having concentration of 100 µg/ ml. From the above 
solution, aliquots of 5 ml were transferred to 10 ml volumetric flasks and final volume 
was made to 10 ml with phosphate buffer pH 6.8. Absorbance values of these 
solutions were measured against blank at 274.5 nm using UV-Visible 
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Spectrophotometer. The percentage purity of drug was calculated by using calibration 
graph method.  
6.1.6. FTIR Study:- 
Fourier Transforms Infra-Red (FTIR) Spectroscopy: 
                             (Robert M. Silverstein, 2003; Becket A. H. and Stenlake J. B., 2005) 
FTIR study was carried out to check identity of drug. Infrared spectrum of 
Metoprolol tartrate was determined on Fourier transform Infrared Spectrophotometer 
using KBr dispersion method. The base line correction was done using dried 
potassium bromide. Then the spectrum of dried mixture of drug and potassium 
bromide was run followed by drug by using FTIR spectrophotometer. The absorption 
maximums in spectrum obtained with the substance being examined correspond in 
position and relative intensity to those in the reference spectrum. 
 
6.1.7. Drug – Polymers Compatibility Study by DSC Analysis:-                                         
Determination of drug-polymer compatibility                                  
 
The proper design and formulation of a dosage form requires consideration of 
the physical, chemical and biological characteristics of all drug substances and 
excipients to be used in the fabricating the product. Each polymer used in the 
formulations was blended with the drug levels that are realistic with respect to the 
final dosage form. Each polymer was thoroughly blended with drug to increase drug- 
polymer molecular contacts to accelerate the reactions if possible. 
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Figure 6.1: Schematic representation of compatibility studies 
 
Differential scanning calorimetry (DSC):  
                                                                           (Chatwal G. R. and Anand  S. K.,  2007) 
Any possible drug polymer interaction can be studied by thermal analysis. The 
DSC study was performed on pure drug, drug+ Carbopol 934 P and drug + HPMC 
K4M. The study was carried out using a Shimadzu DSC Q20 V24.4,116, (Japan). The 
5 mg of sample were heated in a hermetically sealed aluminum pans in the 
temperature range of 25-500ºC at heating rate of 10ºC /min under nitrogen flow of 
50ml/min.  
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7. FORMULATION OF BUCCOADHESIVE FILM 
Formulation design of 2 
3
full factorial design 
           A 2
3
 randomized full factorial design was used in this study. Three factors 
were evaluated,each at two levels and experimental trials were performed on all eight 
possible combinations (Table 7.1). The amount of HPMC K4M as film former (X1), 
and the amount of carbopol 934P as buccoadhesive polymer (X2) and concentration 
of DMSO as penetration enhancer (X3) were selected as independent variables. The 
percent cumulative drug release ( % CDR) at 8
th
 hour, ex-vivo residence time and 
cumulative % permeation at 8
th
 hour respectively were selected as dependent 
variables. Regression polynomials for the individual dependant variables were 
calculated with the help of Design Expert 8.0.2 software (Stat-Ease,Inc,USA) and 
applied to approximate the response surface and contour plots. The general model as 
shown below was generated- 
Y=B0+B1X1+B2X2+B3X3+….+B12X1X2+B13X1X3+B23X2X3+….+B123X1X2
X3 
B1 is estimated coefficient for the factor X1,similarly B2 and B3  are estimated 
coefficients for the factor X2 and X3 respectively. The main effects (X1,X2 and X3) 
represent the average result of changing one factor at a time from its low to high 
value. The interaction terms show how the response changes when three factors are 
simultaneously changed.  
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Table 7.1: Composition of Bucccoadhesive Film of Metoprolol tartrate 
 
 
 
 
 
 
 
Ingredients  BF1 BF2 BF3 BF4 BF5 BF6 BF7 BF8 BF9 
Metoprolol tartrate   
(mg) 
50 50 50 50 50 50 50 50 50 
HPMC K4M 
 %w/v (X1) 
-1 -1 -1 -1 +1 +1 +1 +1 0 
Carbopol 934P 
%w/v (X2)  
-1 -1 +1 +1 -1 -1 +1 +1 0 
DMSO %w/v (X3) -1 +1 -1 +1 -1 +1 -1 +1 0 
                            Independent variables values 
 +1 -1 0 
HPMCK4M (X1) 600 mg 300 mg 450 mg 
Carbopol 934P (X2) 100 mg 50 mg 75 mg 
DMSO (X3) 0.6 ml 0.3 ml 0.45 ml 
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7.2. PREPARATION OF BUCCOADHESSIVE FILM:- 
The buccoadhesive Film were prepared by solvent casting method. Each 2 cm 
film contained 50 mg of  Metoprolol tartrate. 
             Backing layer:   
                       For preparation of backing layer a glass petridish of 9.5 cm diameter 
was used as a casting surface. Backing membrane of ethyl cellulose was fabricated by 
slowly pouring a solution containing 500 mg of ethyl cellulose and 2 % dibutyl 
phthalate in 10 ml of ethanol to the glass petridish and air drying for 1 hr. 
 
Buccoadhesive layer containing drug:  
          3% w/v HPMC K4M was dissolved in 10 ml of ethanol and water (3:2) 
under constant stirring till a clear solution was obtained. To this 1 % w/v neutralized 
carbopol 934P (0.5 g of carbopol 934P was neutralized by approximately 0.2 g of 
sodium hydroxide) and 5 % v/v propylene glycol was added with stirring using 
magnetic stirrer. Then sufficient amount of metoprolol tratrate was added with stirring 
so as to have 50 mg of drug per 2 cm diameter of film. The mixture was stored at low 
temperature in order to remove air bubbles. The resultant clear solution was then 
poured on performed backing layer of ethyl cellulose and allowed to dry undisturbed 
for 4 h at 60 
0
C in the oven to ensure complete removal of solvent. The dried film was 
cut into discs of 2 cm diameter and packed in aluminium foil and stored in 
desiccators. 
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7.3. CALCULATION OF DOSE FOR CONVERTING METOPROLOL 
SUCCINATE IN TO METOPROLOL TARTRATE: 
Metoprolol succinate molecular weight =23.75 
Metoprolol tartrate  molecular weight=25.00 
Conversion factor =1.052631579 
50mg of metoprolol tartrate was equivalent to 52.63mg of  metoprolol          
succinate. 
7.4. CALCULATION OF DOSE FOR BUCCOADHESIVE FILMS: 
2 cm of the buccoadhesive film contains 50 mg. 
Diameter of petridish =9.5 cm 
Calculation of dose: 
9.5 cm of  petridish contains drug=x 
                                                =(9.5/2)X50 
                                                                 = 237.5 mg 
9.5 cm of petridish contains 237.5 mg of  metoprolol tartrate.
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8. EVALUATION OF BUCCOADHESIVE FILM 
 
8.1. Physical Properties of Film:-
    
                               (Lachmann L. Et al., 1987; Bankar G.S. and Rhodes C.T., 1996)
 
 
8.1.1. Appearance: 
 The formulated films visually observed for colour, clarity and transparency. 
8.1.2. Dimension (Diameter and Thickness):                               
                           The Thickness and diameter permits accurate measurements and 
provide information on the variation between Films. The thickness and diameter of 
the Film was determined using a Vernier caliper. Three Films from each type of 
formulation were used and average values were calculated.  
8.2. Folding endurance     
                                           (Pankajkumar, et al., 2012; Ravikumar Reddy, et al., 2012) 
        Folding Endurance of the film was determined by repeatedly folding the films at 
the same place till it breaks. The films was folded in the center, between finger and 
thumb and then opened. This was one folding. The number of times, the film could be 
folded at the same place without breaking gave the value of folding endurance. 
8.3. Swelling studies 
Weight method – swelling studies           (Pankajkumar, et al., 2012) 
 The films were weighed individually (designated as Wo) and placed separately 
in 2% agar gel plates, incubated at 37+1
0
C and examined for any physical changes. At 
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regular 1hr time interval until 3 hours, films were removed from the gel plates and 
excess surface water was removed carefully using filter paper. The swollen films were 
then reweighed (WT) and the swelling index were calculated using the following 
formula: 
 % SW = [(WT – WO) / WO] x 100 
Where, 
 %SW = percentage swelling index; 
 WT = weight of swollen film after time T; 
 WO = original weight of film at zero time; 
8.4. Surface pH                                  (Ayyappan T. and Kasture P.V., 2005)  
 Surface pH of oral cavity was determined in order to investigate the possibility 
of any side effects in a buccal mucosa. Attempt was made to keep the surface close to 
the saliva pH. The formulations were first wetted by adding 1ml distilled water to its 
surface. The surface pH was then recorded by bringing a glass electrode  near  the 
surface of the formulation and allowing it to equilibrate for 1min.  
8.5. Drug content                         (Venkatalakshmi et al.,2011)   
          Uniformity of drug content was determined by assaying the individual films. 
Three films from each batch were powdered individually and each was dissolved in 
100 mL of isotonic phosphate buffer pH 6.8 by stirring on a magnetic stirrer for 1 
hours. The absorbance of each of these solutions was then measured on UV-visible 
spectrophotometer at 274.5 nm. 
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8.6. Ex-vivo Bioadhesion Study:- 
a) Fabrication of the Test Assembly:
                                                            
(Gupta A. et al., 1992) 
  For in-vitro study, an apparatus designed for the determination of 
mucoadhesive bond force was used. Bioadhesion test assembly is shown in figure 8.1. 
  For the designing of the apparatus, two pan weighing balance was used. The 
pan from the left side was replaced with a glass vial hanged with the thread. Another 
glass vial inside the glass bottle was placed below this vial in such a way that both 
(upper and lower) vials just touch each other. The two sides were balanced so that the 
right side exactly 2 gm heavier than left side by placing appropriate weight in right 
side pans. 
  Using this bioadhesion test assembly, the bioadhesion strength expressed in 
weight (g) required for the detachment of the film from the mucosa was determined. 
b) Measurement of Adhesion Force:
                                                            
(Cafaggi S. et al., 2005) 
  Measurement of adhesion force was determined by using bovine buccal 
mucosa which was obtained from slaughter house. The underlying tissues were 
separated and washed thoroughly with phosphate buffer solution (pH 6.8). The 
membrane was then tied to the bottom of the lower vial using rubber band. The vial 
was kept in glass bottle which was filled with phosphate buffer solution at 37 ± 1 
0
C 
in such way that buffer just reaches the surface of mucosal membrane and kept it 
moist. The films to be tested was stuck on the lower side of the hanging Glass vial by 
using adhesive tape and the weight (2 gm) 
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Fig. 8.1: Bioadhesion test assembly   
on the right pan was removed. This lowered the left side of the pan along with the 
film over the mucosa. It was kept undisturbed for three minutes and the weights are 
added on right side of pan till the film just separated from the membrane surface. The 
excess weight on the right pan i.e. total weight minus 2 gm was taken as measure of 
bioadhesive strength. Bioadhesive force was calculated by using following equation. 
                                                             Bioadhesive Strength 
Bioadhesive force = 
_______________________________________          
× 9.81 
   100 
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8.7. Ex-Vivo Residence Time: -                                      (Patel V. M. et al., 2007)
 
  The ex-vivo Residence time was examined after application of the buccal film 
on freshly cut goat buccal mucosa. The fresh goat  buccal mucosa was tied on the 
glass slide and a mucoadhesive core side of each film was wet with 1 drop of 
phosphate buffer (pH 6.8) and pasted to the goat buccal mucosa by applying a light 
force with a fingertip for 50 seconds. The glass slide was then put in the beaker, 
which was filled with 200 ml of the phosphate buffer and kept at 37
°
C± 1
°
C. After 2 
minutes, a slow stirring rate was applied to stimulate the buccal cavity environment 
and film adhesion was monitored for 14 hours. The time for the film to detach from 
the goat buccal mucosa was recorded as the Residence time. 
8.8. In- Vitro Drug Release Study:-
                            
                                                                                                                                   
(Nagendra kumar et al.,2011) 
  The influence of technologically defined condition and difficulty in simulating 
in- vivo conditions has led to the development of a number of in- vitro release 
methods for buccal formulations, however, no standard method has yet been 
developed. In-vitro release rate of buccoadhesive Film of Metoprolol tartrate was 
carried out using rotating paddle apparatus (USP Type II). The dissolution medium 
consisted of 250 ml of phosphate buffer (pH 6.8). The release study was performed at 
37
°
C ± 0.5
°
C with a rotation speed of 50 rpm. The sample (5 ml) was withdrawn at 
time interval of 30 and 60 minutes up to 8 h and replaced with 5 ml of dissolution 
media each time to maintain the sink conditions. The amount of Metoprolol tartrate 
released was determined spectrophotometrically at 274.5 nm. 
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Table 8.1: Parameters were used for the dissolution study 
Apparatus 
USP Dissolution  apparatus 
(Type II) 
Dissolution medium Phosphate buffer (pH 6.8) 
Temperature 37 +  0.5 °C 
Volume 250 ml 
Speed 50 rpm 
Sample withdrawn 5 ml 
Running Time 8 hrs  
 
8.9.In-vitro buccal permeation:                                    (Nagaraju.K et al., 2011) 
The in-vitro buccal permeation study of metoprolol tartrate through goat 
buccal mucosa was performed using Franz diffusion cell. A specimen of fresh goat 
buccal mucosa was mounted between donar and receptor compartments. The film was 
placed on the mucosa, and the compartments were filled with 1ml of phosphate buffer 
pH 6.8. The receptor compartment was filled with isotonic phosphate buffer pH 6.8 
maintained at 37.0±0.2
°
C and hydrodynamics in the receptor compartment were 
maintained by stirring magnetically at 50 rpm. Aliquots of 1 ml sample were 
withdrawn at predetermined time intervals and analyzed UV spectrophotometer at 
274.5nm. 
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                             Fig. 8.2: Franz diffusion assembly 
8.10. Histopathological Studies: 
             Histopathological evaluation of goat buccal mucosa tissue (control)incubated 
in phosphate buffer saline solution pH 6.8 was compared with that treated with buccal 
film for 8 hr. the tissue was properly washed twice using normal saline solution to 
remove the adhered tissues and protein. The tissue was fixed with 10 %formalin, 
routinely processed and set in paraffin. Paraffin sections were cut on glass slides and 
stained with hematoxylin and eosin. Examine the transverse sections of treated goat 
buccal mucosa under light microscope to detect any cellular damage to buccal mucosa 
tissue. 
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8.11. Kinetics of In-vitro Drug Release:
          
(Brahmankar D.M. and Jaiswal S.B., 2006)
 
To study the release kinetics of in-vitro drug release, data was applied to 
kinetic models such as zero order, first order, Higuchi and Korsmeyer- Peppas. 
 Zero order: 
Where    K0 - is the zero-order rate constant expressed in units of 
concentration/time   
                          t -is the time in hrs. 
 First order: 
Where   C0 - is the initial concentration of drug, 
                
                         K - is the first order constant 
                 t - is the time in hrs.  
 Higuchi: 
 
Where   Qt - is the amount of the release drug in time t, 
                  K- is the kinetic constant and  
                       t- is time in hrs. 
 Korsmeyer Peppas: 
 
Where   Mt  -  represents amount of the released drug at time t,  
C = K0t                                                                                                               
LogC = LogC0 – Kt / 2.503                                                                             
Qt = Kt
1/2
                                                                                                          
Mt / M∞ = Kt n                                                                                                                                                                                                    
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            M∞ -  is the overall amount of the drug (whole dose) released after 8 hrs  
                 K -  is the diffusion characteristic of drug/ polymer system constant  
                  n - is a diffusional exponent that characterizes the mechanism of 
release of drug.  
The value of n indicates the drug release mechanism related to the geometrical 
shape of the delivery system, if the exponent n = 0.5, then the drug release mechanism 
is Fickian diffusion. If n < 0.5 the mechanism is quasi-Fickian diffusion, and  0.5 < n 
< 1.0, then it is non-Fickian or anomalous diffusion and when n = 1.0 mechanism is 
non Fickian case II diffusion, n> 1.0 mechanism is non Fickian super case II. 
8.12. Statistical analysis of response by design expert software:   
                                                                                             (Prakash Rao B.et al.,2011) 
        Design Expert 8.0.2 software was used for the analysis of effect of each variable 
on the designated response. Pareto charts were made for the analysis of each response 
coefficient for its statistical significance. Quantitative and qualitative contribution of 
each variable on each of the response was analyzed. The significant response 
polynomial equations generated by design expert were used to validate the statistical 
design. Response surface pictelots were generated to visualize the simultaneous effect 
of each variable on each response parameter. Possible interactions between X1X2, 
X2X3, and X1X3 were also studied and analyzed. 
Validation of Experimental Design: 
                The polynomial equations were utilized for validation of the experimental 
design. An extra  check point formulation BF9 was prepared with the predicted value 
for  of in-vitro drug release  (%CDR at 8
th 
hr),Cumulative  permeability at 8
th
hr and  
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ex-vivo residence time. Experimental value were determined by formulating and 
evaluating BF9 and close resemblance between predicted and experimental value 
indicated validity of the  generated model .Finally  an optimized formulation was 
selected on the basis of higher in-vitro drug after 8hr (%CDR),higher  ex-vivo 
residence time ,and higher cumulative %permeability at 8%hr with good desirability 
factor using software analysis. 
8.13. Stability Study: -
                                                                                             
(Nakhat P. D. et al., 2007) 
 The purpose of stability testing is to provide evidence on how the quality of a 
drug substance or drug product varies with time under the influence of a variety of 
environmental factors such as temperature, humidity and light, enabling 
recommended storage conditions, re-test periods and shelf-lives. Generally, the 
observation of the rate at which the product degrades under normal room temperature 
requires a long time. To avoid this undesirable delay, the principles of accelerated 
stability studies are adopted.  
From the prepared film formulation BF4 showed appropriate balance between    
In-vitro drug release and bioadhesive property, Hence formulation BF4 was selected 
for the stability study. The study was carried out to observe the effect of temperature 
on optimized formulation (BF4). Stability studies were carried out at 40°
 
C / 75% RH 
for the formulation BF4 for 3 months. The buccal mucoadhesive Film were stored at 
40°C/75% RH in closed high density polyethylene bottles for 3 months. The samples 
were withdrawn after periods of 1 month, 2 month and 3 month. The samples were 
analyzed for its Appearance, Surface pH , Ex-vivo residence time, Drug content and 
In vitro drug permeation. 
  
 
 
RESULTS 
AND 
DISCUSSION 
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9. RESULTS AND DISCUSSION 
 
9.1. Identification of Drug:-  
9.1.1. Organoleptic Properties:
 
 Colour        : White  
 Odour         : Odorless 
 Taste           : Tasteless  
 Appearance: Fine powder 
9.1.2. Melting Point:
 
Melting point values of sample utilized in the formulation was found to be in 
range of 136°C. Hence, results were complied the limits specified in official Book. 
9.1.3. Solubility Study:
 
Table 9.1: The solubility of Metoprolol tartrate in various solvents 
 
 
 
 
 
 
 
 
 
Name of solvent Parts of solvent required 
per part of solute 
Solubility 
Distilled water 10 Very Soluble 
Ethanol (95%) 40 Freely soluble 
Chloroform 400 Sparingly soluble 
Ether 600 Practically 
insoluble 
Phosphate buffer pH 
6.8 
50 Freely soluble 
Phosphate buffer pH 
7.4 
70 Freely soluble 
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9.1.4. UV Spectrophotometric Study:
 
The absorption maximum for Metoprolol tartrate was found to be 274.5 nm. 
 
 
Fig. 9.1: λmax of Metoprolol tartrate in phosphate buffer pH 6.8 
9.1.5. Calibration Curve of Metoprolol tartrate: 
UV absorption spectrum of Metoprolol tartrate in phosphate buffer pH 6.8 
shows λmax at 274.5 nm. Absorbances obtained for various concentrations of 
Metoprolol tartrate are given in Table 9.2. The graph of absorbance vs. concentration 
for Metoprolol tartrate was found to be linear in the concentration range of 10-60      
μg /ml. This drug obeys Beer- Lambert‟s law in the range of 10-60 μg /ml. 
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Table 9.2: Data of concentration and absorbance for Metoprolol tartrate in Phosphate 
buffer pH 6.8 
        Sr. No. Concentration 
(µg/ml) 
Absorbance 
1 0 0.000 
2 10 0.040 
3 20 0.081 
4 30 0.120 
5 40 0.165 
6 50 0.201 
7 60 0.242 
  
 
Fig. 9.2: Standard graph of Metoprolol tartrate in Phosphate buffer pH 6.8 
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Table 9.3:  Data for Calibration Curve Parameters 
 
 
 
 
 
 
9.1.6. Percentage Purity of Drug: 
The percentage purity of drug was calculated by using calibration graph 
method. 
Table 9.4:  Percentage purity of drug 
  
 
 
 
 
The official percentage purity of Metoprolol tartrate is not less than 99.00% 
and not more than 101.00%. So, it can be declared as pure drug. 
 
 
Sr. No. Parameters Values 
1 Correlation coefficient (r) 0.9998 
2 Slope 0.247 
3 Intercept 0.0094 
Sr. No. 
Percentage purity 
(%) 
Average percentage 
purity (%) 
1 99.56  
99.58 
2 99.82 
3 99.38 
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9.1.7. Fourier Transforms Infra-Red (FTIR) Study: 
 
Fig. 9.3: FT-IR spectra of Metoprolol tartrate 
Table 9.5: Interpretation of FTIR spectra of Metoprolol tartrate 
O-H Stretching  3752.18 
C-O-C Stretching Aliphatic 1114.34 
C- N Stretching 1242.27 
N-H bend Aliphatic 1615.06 
N-H Stretch 2 Amine 3151.25 
From the above figure 9.3, it can be seen that, the major functional group 
peaks observed in spectra of Drug with all the polymers remains unchanged as 
compared with spectra of Metoprolol tartrate. So from the above IR spectra it can be 
observed that the identified as Metoprolol tartrate. 
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9.2. Drug – polymer compatibility Study by DSC Analysis 
 Differential Scanning Calorimetry  (DSC) Analysis: 
            
 
Fig. 9.4: DSC thermo gram of Metoprolol tartrate 
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Fig. 9.5: DSC thermo gram of Metoprolol tartrate +                                                
Carbopol 934 P  
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Fig. 9.6: DSC thermo gram of Metoprolol art rate + HPMC K4M 
 
 
Table 9.6: Data for DSC thermo gram parameters 
Sr. 
No. 
DSC thermo gram sample Onset temperature 
(°C) 
Peak temperature 
(°C) 
1 
Metoprolol tartrate 
140.94 145.33 
2 
Metoprolol tartrate+ 
Carbopol934P 
136.58 144.26 
3 
Metoprolol tartrate+ HPMC 
K4M 
138.43 145.88 
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DSC thermo gram showed that there was no any major difference in onset 
temperature and peak temperature, when compared with thermo gram of pure drug. 
So, it was found that no interaction between drug and polymers. 
 
9.3. PHARMACOTECHNICAL CHARACTERISTICS OF THE FILMS: 
9.3.1. Dimension (Thickness and diameter) 
Thickness and diameter specifications may be set on an individual product 
basis. There were no marked variations in the thickness and diameter of films within 
each formulation indicating uniform behavior of film throughout the sealing process. 
The size (diameter) and thickness of the films of all formulations were reported in 
Table 9.7.  
9.3.2. Determination of Weight of films 
 From each batch randomly three films were selected and weighed.  The weight 
variations of films of all formulations were reported in Table 9.7. 
9.3.3. Folding endurance: 
     Use of less amount of plasticizer was observed to cause brittleness in the 
medicated discs, but use of greater amount of plasticizer (1mL plasticizer per 10 mL) 
displayed little opaqueness and good folding endurance. The values were reported in 
the table 9.7 
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                       Table 9.7: Pharmacotechnical evaluation of buccoadhesive films  
Formulation 
Code 
Dimension Weight of the 
film 
(mg) * ± SD 
Folding 
endurance * ± 
SD 
Diameter 
(cm)* ± SD  
Thickness 
(mm)* ± SD 
BF1 1.98 ± 0.08 1.03 ± 0.017 231.3 ± 0.67 310.66 ± 1.15 
BF2 2.04 ± 0.048 0.92 ± 0.060 279.2 ± 0.05 315.33± 4.93 
BF3 2.04 ± 0.048 1.57 ± 0.479 244.8 ± 0.44 334.33 ± 11.59 
BF4 2.06 ± 0.048 1.47 ± 0.110 329.8 ± 0.94 340.00 ± 4.00 
BF5 2.02 ± 0.074 1.78 ± 0.064 262.4± 0.01 353.00 ± 07.81 
BF6 2.00 ± 0.063 1.84 ± 0.094 304.8 ± 0.05 343.3 ± 13.65 
BF7 2.00 ± 0.063 1.06 ± 0.015 358.4 ± 0.95 359.00 ± 13.47 
BF8 2.02 ± 0.074 1.14 ± 0.191 272.4 ± 0.77 347.00±7.54 
BF9# 2.08±0.054 1.92± 0.052 258.5±0.04 350.6±10.26 
All the values were expressed as mean± S.D.,*n=3,#extra design check point 
formulation 
9.3.4 In-Vitro Swelling Study:-                                     
                                     Table 9.8: In-vitro swelling study 
 
 
 
 
 
 
 
 
 
                    All the values were expressed as mean± S.D.,*n=3 
Sr.No. Formulation code Swelling index(%) 
1 BF1 29.72±0.660 
2 BF2 28.86±0.890 
3 BF3 39.06 ±0.690 
4 BF4 42.39±0.400 
5 BF5 21.41±0.370 
6 BF6 32.70±0.670 
7 BF7 41.30±0.130 
8 BF8 50.13±0.420 
9 BF9 45.00±1.040 
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                                     Fig.9.7: In-vitro swelling index 
The bioadhesion and drug release profile are dependent upon swelling 
behavior of the Film. Swelling index was calculated with respect to time. Swelling 
index increased as the weight gain by the Film increased proportionally with the rate 
of hydration. The films started to swell within 5 min due to presence of swellable 
HPMC K4M and carbopol 934P, and maximum degree of swelling was observed after 
30 min. 
The films containing high level of carbopol 934P (BF3, BF4, BF7, BF8) 
exhibited higher degree of swelling as compared to films containing low level of 
carbopol 934P (BF1, BF2, BF5, BF6). This is be due to the concentration based 
swelling behavior of carbopol 934P available for swelling, more will be the swelling 
index which is beneficial for buccoadhesion. Swelling phenomenon of the polymers 
makes strong secondary hydrogen bonding with buccal mucosa and thus results in 
mucoadhesion. Swelling results in the formation of thick swollen mass which provide 
unidirectional release of drug in sustained manner. 
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9.3.5. Surface pH Study:- 
                            Table 9.9: Surface pH of Buccoadhesive Film 
 
        *All the values are expressed as mean± SD, n=3. 
 
Fig. 9.8: Surface pH of Buccoadhesive Film 
The results given in the table and its graphical representation showed that the 
surface pH of all the Film was within the range of 6.02±0.157 to 7.23±0.080.  
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Surface pH
Sr.No. Formulation code Surface pH* 
1 BF1           7.04±0.047  
2 BF2 6.84± 0.181 
3 BF3 6.31 ±0.157 
4  BF4 6.23 ±0.080 
5 BF5 6.98 ±0.080 
6 BF6 6.50 ±0.294 
7 BF7 6.02 ±1.000 
8 BF8 6.84 ±0.008 
9 BF9 6.04 ±0.294 
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These results indicated that there is no risk of mucosal damage or irritation while 
administering these formulations on buccal mucosal region. 
9.3.6.Content uniformity:- 
  Table 9.10: Content uniformity of buccal film 
Sr.No. Formulation code Percentage drug content 
1 BF1 99.26±1.03 
2 BF2 99.92±0.49 
3 BF3 98.93±0.85 
4 BF4 98.76±0.28 
5 BF5 96.13±1.24 
6 BF6 96.95±1.78 
7 BF7 98.93±0.49 
8 BF8 98.36±1.59 
9 BF9 97.97±0.49 
All the values are expressed as mean± SD, n=3. 
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Fig. 9.9: percentage drug content of Buccoadhesive Film 
The content uniformity of the prepared buccoadhesive film of the metoprolol tartrate 
displayed more than 96% drug content. The drug content of prepared buccoadhesive 
films have within the range of 99.0 to 101.0% as specified in the official monographs. 
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9.3.7. Ex-Vivo Bioadhesion Study:- 
Table 9.11: Effect of bioadhesive polymers on bioadhesive strength and force    
                        All the values are expressed as mean± SD, n=3. 
 
 
            Fig. 9.10: Effect of Bioadhesive polymers on Bioadhesive strength             
            The results of ex-vivo buccoadhesive strength for metoprolol tartrate buccal 
films are shown in table 9.11. The formulations (BF1 to BF8) exhibited bucco 
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Buccoadhesive Strength
Sr.No. Formulation code Buccoadhesive 
Strength (gm) 
Buccoadhesive 
Force(N) 
1 BF1 32.00±1.000 3.13±0.09 
2 BF2 34.00±1.000 3.30±0.01 
3 BF3 36.00±1.000 3.52 ±0.09 
4 BF4 35.00±1.000 3.30±0.24 
5 BF5 32.00±1.520 3.16±0.14 
6 BF6 31.00±1.000 3.03±0.19 
7 BF7 38.00±2.000 3.72±0.19 
8 BF8 39.00±3.200 3.82±0.31 
9 BF9 31.00±2.600 3.03±0.25 
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adhesion strength of 31.00±1.00 to 36.00±1.00 gm and the cut off value for 
buccoadhesion of a dosage form is 32gm. Thus BF1 was rejected and the rest of the 
formulations containing high level of carbopol 934 P (BF3,BF4,BF7,BF8) exhibited 
higher buccoadhesive strength than BF2,BF5,BF6 formulation which may be due to 
surface adhesion phenomenon as well as due to formation of secondary hydrogen 
bonds with mucosa as a result of rapidswelling of carbopol 934P.B uccoadhesion is 
also regulated by the addition of HPMC K4M. It has synergistic effect on 
buccoadhesiove strength over carbopol 934P, correspondingly BF7,BF8 displayed  
highest buccoadhesive strength. 
 
   9.3.8. Ex-Vivo Residence Time:- 
                           Table 9.12: Residence time of Buccoadhesive Film   
 
 
 
 
 
                          
                    *All the values are expressed as mean± SD, n=3 
Sr.No. Formulation code Residence time (hours) 
1 BF1 07.06±0.66 
2 BF2 10.41±0.07 
3 BF3 12.34 ±0.11 
4 BF4 12.81±0.57 
5 BF5 11.96±0.48 
6 BF6 11.68±0.54 
7 BF7 13.03±0.55 
8 BF8 13.05±0.03 
9 BF9 10.68±0.51 
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.      
                    Fig. 9.11: Data for the ex-vivo residence time 
      The ex-vivo Residence time was examined after application of the buccal films on 
freshly cut goat buccal mucosa. The result showed in Table 9.12, revealed that the 
mean adhesion time was increased in the formulation batches containing Carbopol 
934P: HPMC K4M combination. This may be due to the flexibility of   Carbopol 934 
P chains, which easily diffuses and interpenetrates into the mucin and get entangled 
with that of mucin. The mucoadhesive time on goat buccal mucosa ranged from 7.06 
to 12.05 hours. The films containing high level of carbopol 934P (BF3,BF4,BF7,BF8) 
showed higher residence time of  11.34 to 12.05 hr as films containing low level of 
carbopol 934P (BF1,BF2,BF5,BF6) that show residence time of 7.06 to 10.68hr.This 
may due to surface adhesion phenomenon  as well as due to formation of secondary 
hydrogen bonds with goat buccal mucosa as a result of  rapid swelling of carbopol 
934P. BF7 and BF8 show higher residence time than BF3 and BF4 due to presence of 
HPMC K4M at high level. Hence it can be concluded that ex-vivo residence time 
increased with increase in the HPMC concentration in the formulation. 
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9.3.9. In-Vitro Drug Release Study:- 
Table 9.13: Drug release data of formulation BF1 
Sr. No. Time (hours) Cumulative % drug 
release 
1 0 0.000±0.00 
2 0.5 23.15±1.3058 
3 1 26.84±1.3887 
4 2 31.156±1.0319 
5 3              36.793±1.3766 
6 4 43.716±1.1168 
7 5 53.82±0.9690 
8 6 64.66±0.3893 
9 7 77.68±1.5326 
10 8 92.19±0.6022 
 
 
                       Fig. 9.12: Drug release profile of formulation BF1 
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Table 9.14: Drug release data of formulation BF2 
Sr. No. Time (hours) Cumulative % drug 
release 
1 0 0.000±0.00 
2 0.5 20.69±0.62 
3 1 24.57±0.37 
4 2 31.03±0.90 
5 3 34.43±0.76 
6 4 42.96±0.29 
7 5 53.34±0.32 
8 6 63.00±0.24 
9 7 75.55±0.81 
10 8 89.37±0.41 
 
 
 
 
             
Fig. 9.13: Drug release profile of formulation BF2 
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Table 9.15: Drug release data of formulation BF3 
Sr. No. Time (hours) Cumulative % drug 
release 
1 0 0.000±0.00 
2 0.5 20.11±0.70 
3 1 24.64±0.42 
4 2 36.18±0.19 
5 3 41.40±1.07 
6 4 51.56±0.30 
7 5 56.41±0.35 
8 6 63.49±0.45 
9 7 71.88±0.47 
10 8 80.26±0.67 
 
           
Fig. 9.14: Drug release profile of formulation BF3 
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Table 9.16 Drug release data of formulation  BF4 
Sr. No. Time (hours) Cumulative % drug 
release 
1 0 0.000±0.00 
2 0.5 21.6±0.37 
3 1 25.74±0.49 
4 2 37.49±0.17 
5 3 41.85±0.44 
6 4 52.22±0.20 
7 5 57.41±0.58 
8 6 65.21±0.37 
9 7 72.81±0.14 
10 8 84.29±0.46 
 
 
Fig. 9.15: Drug release profile of formulation BF4 
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Table 9.17: Drug release data of formulation  BF5 
Sr. No. Time (hours) Cumulative % drug 
release 
1 0 0.000±0.00 
2 0.5 17.19±0.32 
3 1 22.97±0.50 
4 2 33.60±0.48 
5 3 39.70±0.09 
6 4 48.62±0.42 
7 5 54.41±0.58 
8 6 61.54±0.57 
9 7 70.35±0.48 
10 8 77.54±0.51 
 
             
Fig. 9.16: Drug release profile of formulation BF5 
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Table 9.18: Drug release data of formulation BF6 
Sr. No. Time (hours) Cumulative % drug 
release 
1 0 0.000±0.00 
2 0.5 17.52±0.13 
3 1 22.36±0.32 
4 2 32.94±0.32 
5 3 38.39±0.38 
6 4 47.42±0.26 
7 5 52.2±0.20 
8 6 61.13±0.13 
9 7 68.95±0.42 
10 8 74.80±0.54 
 
              
Fig. 9.17: Drug release profile of formulation BF6 
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Table 9.19: Drug release data of formulation BF7 
Sr. No. Time (hours) Cumulative % drug 
release 
1 0 0.000±0.00 
2 0.5 17.52±0.05 
3 1 22.03±0.43 
4 2 33.01±0.31 
5 3 37.82±0.32 
6 4 45.76±0.27 
7 5 52.26±0.24 
8 6 59.87±0.25 
9 7 68.93±0.35 
10 8 73.56±0.42 
 
 
Fig. 9.18: Drug release profile of formulation BF7 
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Table 9.20: Drug release data of formulation BF8 
Sr. No. Time (hours) Cumulative % drug 
release 
1 0 0.000±0.00 
2 0.5 14.92±0.82 
3 1 19.91±0.57 
4 2 31.69±0.21 
5 3 36.42±0.40 
6 4 44.38±0.62 
7 5 48.54±0.39 
8 6 57.88±0.66 
9 7 66.71±0.88 
10 8 71.29±0.62 
 
 
Fig. 9.19: Drug release profile of formulation BF8 
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Table 9.21: Drug release data of formulation BF9 
Sr. No. Time (hours) Cumulative % drug 
release 
1 0 0.000±0.00 
2 0.5 20.07±0.07 
3 1 23.93±0.18 
4 2 34.54±0.19 
5 3 40.43±0.40 
6 4 47.28±0.36 
7 5 51.93±0.25 
8 6 61.48±0.51 
9 7 69.80±0.52 
10 8 76.31±0.51 
 
 
Fig. 9.20: Drug release profile of formulation BF9 
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Fig. 9.21: Comparative Drug release profile of all Buccoadhesive Film. 
In-vitro drug release studies revealed that the release of Metoprolol tartrate 
from different formulations varies with the characteristics and composition of matrix 
forming polymers as shown in figures 9.12 to 9.20. Films containing low level of 
HPMC K4M (BF1,BF2,BF3,BF4)displayed higher in-vitro drug release  (92.19± 0.60 
to 80.26±0.67)than formulations containing higher level of  HPMC K4M 
(BF5,BF6,BF7,BF8)that displayed only (71.29±0.62 to 77.54±0.51 ) drug release 
after 8hr which may due to increase viscosity offered by the gelling of the hydrophilic 
HPMC K4M polymer. The increased viscosity of formulation resulted in a 
corresponding decrease viscosity of by the gelling of the hydrophilic HPMC K4M 
polymer. The increased viscosity of formulation resulted in a corresponding decrease 
in the release. A similar observation has been obtained by other reference drug. 
Where as decrease in metoprolol tartrate release was obtained on increasing the 
concentration of HPMC and carbopol 934P. Though  highest %CDR of  92.19 
±0.60% at 8
th
 was recorded for BF1, the formulation was rejected based on poor  ex-
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vivo  residence time, thus BF4 was considered as second best formulation in terms of 
%CDR (84.29%)and least by BF8 (71.29%) which is showing an inverse relation 
between concentration of HPMC K4M and in-vitro drug release. In formulations BF1, 
BF2, BF3, BF4 drug release with increasing the concentration of carbopol 934 P. 
Since carbopol 934P is insoluble in stimulated saliva and swelling behavior of 
carbopol 934P is attributed to unchanged COOH group that get hydrated by forming  
hydrogen bonds on imbibing with water and therefore extending polymer chain. It 
was observed that films containing combination of high levels of both carbopol934P 
and HPMCK4M exhibited delayed drug release indicating better matrix 
characteristics. Strong matrix integrity inhibits the entry of dissolution media and 
delays the dissolution of drug.  
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9.3.10. In-Vitro buccal permeation:- 
Table 9.22: Drug permeation data of formulation BF1 
Sr. No. Time (hours) Cumulative % drug 
permeation 
1 0 0.000±0.00 
2 1 4.13±0.37 
3 2 13.85±0.87 
4 3 16.03±2.62 
5 4                  21.88±0.30 
6 5 23.65±0.21 
7 6 29.64±0.190 
8 7 35.93±1.20 
9 8 39.60±1.50 
            
 
                               Fig. 9.22: Drug permeation profile of formulation BF1 
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Table 9.23: Drug permeation data of formulation BF2 
Sr. No. Time (hours) Cumulative % drug 
permeation 
1 0 0.000±0.00 
2 1 5.59±0.15 
3 2 11.18±0.09 
4 3 16.92±0.10 
5 4 22.57±0.06 
6 5 27.59±0.46 
7 6 32.96±1.10 
8 7 36.41±0.11 
9 8 38.62±0.18 
      
                 
Fig. 9.23: Drug permeation profile of formulation BF2 
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Table 9.24: Drug permeation data of formulation BF3 
Sr. No. Time (hours) Cumulative % drug 
permeation 
1 0 0.000±0.00 
2 1 6.32±0.37 
3 2 11.36±0.27 
4 3 17.65±0.20 
5 4 22.81±0.24 
6 5 30.98±2.20 
7 6 35.31±1.164 
8 7 38.10±0.94 
9 8 40.07±0.06 
       
                 
Fig. 9.24: Drug permeation profile of formulation BF3 
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Table 9.25:Drug permeation data of formulation BF4 
Sr. No. Time (hours) Cumulative % drug 
permeation 
1 0 0.000±0.00 
2 1 07.08±0.05 
3 2 13.25±1.16 
4 3 17.00±0.14 
5 4 22.91±1.09 
6 5 27.72±1.38 
7 6 32.59±0.37 
8 7 37.51±0.90 
9 8 42.68±1.35 
 
 
 
          
                           Fig. 9.25: Drug permeation profile of formulation BF4 
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Table 9.26:  Drug permeation data of formulation BF5 
Sr. No. Time (hours) Cumulative % drug 
permeation 
1 0 0.000±0.00 
2 1 11.97±0.84 
3 2 15.04±0.71 
4 3 19.09±0.12 
5 4 22.17±1.8 
6 5 24.63±0.32 
7 6 26.62±1.38 
8 7 34.61±0.75 
9 8 36.64±0.18 
     
                
Fig. 9.26: Drug permeation profile of formulation BF5 
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Table 9.27: Drug permeation data of formulation BF6 
Sr. No. Time (hours) Cumulative % drug 
permeation 
1 0 0.000±0.00 
2 1 12.32±0.23 
3 2 14.86±0.55 
4 3 19.63±0.05 
5 4 21.84±0.71 
6 5 24.36±0.43 
7 6 32.44±3.31 
8 7 34.79±1.62 
9 8 38.40±0.70 
 
              
Fig. 9.27: Drug permeation profile of formulation BF6 
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Table 9.28: Drug permeation data of formulation BF7 
Sr. No. Time (hours) 
Cumulative % drug 
permeation 
1 0 0.000±0.00 
2 1 09.96±0.91 
3 2 16.01±0.23 
4 3 20.02±0.23 
5 4                22.17±0.22 
6 5 30.77±0.23 
7 6 35.85±0.43 
8 7 37.04±0.27 
9 8 41.21±0.12 
 
           
                     Fig. 9.28: Drug permeation profile of formulation BF7 
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              Table 9.29:  Drug permeation of formulation BF8 
Sr. No. Time (hours) Cumulative % drug 
permeation 
1 0 0.000±0.00 
2 1 05.20±0.05 
3 2 11.52±1.14 
4 3 12.86±0.76 
5 4 27.92±0.55 
6 5 32.26±0.62 
7 6 35.68±1.28 
8 7 38.92±0.92 
9 8 41.84±0.54 
 
             
                   Fig. 9.29: Drug permeation profile of formulation BF8 
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Table 9.30: Drug permeation data of formulation BF9 
Sr. No. Time (hours) Cumulative % drug 
permeation 
1 0 0.000±0.00 
2 1 05.20±0.05 
3 2 08.84±1.57 
4 3 11.99±0.10 
5 4 27.45±0.37 
6 5 31.52±1.00 
7 6 33.54±0.00 
8 7 33.18±2.30 
9 8 37.08±0.69 
            
              
                       Fig. 9.30: Drug permeation profile of formulation F9 
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Fig. 9.31: Comparative Drug Permeation profile of all Buccoadhesive Film. 
In-vitro drug permeation studies revealed that the release of Metoprolol 
tartrate from different formulations varies with the characteristics and composition of 
matrix forming polymers as shown in figures 9.22 to 9.30.  
Metoprolol tartrate being hydrophilic with log P value of 1.9  exhibits high 
permeability buccal mucosa and there is a need to enhance its buccal mucosa and 
there is a need to enhance its buccal permeation with help of permeation enhancer that 
causes perturbation and dissolution of paracellular fluid, enhancing its paracellular of 
transport. Based on this fact, different concentrations of DMSO were tried to improve 
the permeation of metoprolol tartrate through buccal mucosa. The results suggested 
that on increasing the concentration of DMSO up to 6%, permeability of drug 
increased. 
In the experimental design, formulation BF2,BF4,BF6 and BF8 containing 
high level of DMSO showed higher permeation of metoprolol tartrate than 
formulations BF1,BF3,BF5 and BF7 which is Highlighting the significance of level of 
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DMSO. Amongst all the films containing high levels of DMSO, the descending order 
for permeability coefficient was BF8>BF4>BF6>BF2 and it can be concluded that 
proper formulation optimization is essential. 
 
9.3.11. Histopathological studies: 
 
Fig 9.32 Histopathological evaluation of transverse section of goat buccal 
mucosa treated with optimized formulation BF4 
    The goat buccal mucosa specimen at the end of  permeation study of 
optimized formulation BF4 was subjected to histopathological evaluation. The 
microscopic observation of the transverse section showed no damage to the buccal 
mucosa at cellular level. All the layers mucus,stratum distendum,strtum basale,basal 
lamina and submucosa were found to be intact establishing the non-toxicity of the 
optimized film. 
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9.3.12.Kinetics for Drug Release: 
Table 9.31: Drug release kinetic studies of Buccoadhesive Film 
 
Fig. 9.33: Zero order curve of formulation BF1 
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Code Zero order First order Higuchi Korsemeyer- 
Peppas 
Best fit 
model 
R
2
 K0 
(mg/h
−1
) 
R
2
 K1 (h
−1
) R
2
 K  
(mg h
−1/2
) 
R
2
 N 
BF1 0.9561 11.2770 0.9031 0.2191 0.9556 26.67 0.9416 0.0512 Zero 
order 
BF2 0.9597 11.0392 0.9164 0.2065 0.9562 26.09 0.9500 0.0541 Zero 
order 
BF3 0.9240 6.9175 0.9814 0.1847 0.9934 26.19 0.9924 0.1276 Higuchi 
BF4 0.9235 11.0773 0.9723 0.1964 0.9904 27.03 0.9877 0.1116 Higuchi 
BF5 0.9363 10.7455 0.9867 0.1753 0.9928 25.54 0.9941 0.1262 Peppas   
BF6 0.9376 9.3129 0.9887 0.1660 0.9924 24.8564 0.9936 0.1247 Peppas  
BF7 0.9366 10.0865 0.9868 0.1623 0.9912 24.47 0.9926 0.1232 Peppas   
BF8 0.9463 9.6531 0.9882 0.1546 0.9893 23.72 0.9938 0.1286 Peppas 
BF9 0.9204 10.5770 0.9826 0.1724 0.9916 25.40 0.9869 0.1198 Higuchi 
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Fig. 9.34: Zero order curve of formulation BF2 
 
Fig. 9.35: Higuchi plot curve of formulation BF3 
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Fig. 9.36: Higuchi plot curve of formulation BF4 
 
 
Fig. 9.37: Peppas curve of formulation BF5 
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Fig. 9.38: Peppas curve of formulation BF6 
 
Fig. 9.39: Peppas curve of formulation BF7 
 
Fig. 9.40: Koresmeyer peppa‟s curve of formulation BF8 
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Fig. 9.41: Higuchi plot curve of formulation BF9 
                 Further to characterize the release mechanism of Metoprolol tartrate from 
buccoadhesive Film, the dissolution data was subjected to the different model such as 
zero- order, first order, Korsmeyer- peppas  and matrix- Higuchi diffusion  models.  
9.3.13. Statistical analysis of response by design expert software 
Based on the results obtained for ex-vivo residence time, %CDR at 8
th
 hr and 
cumulative %drug permeation at  8
th
 hr, the response polynomial coefficients were 
determined in order to evaluate each response. Each response coefficient was studied 
for its statistical significance by Pareto charts as shown in figure. Pareto charts 
establish „t‟value of effect that is studied by two limit lines namely Bonferroni limit 
line (t value of effect =3.752)and t limit line (t value effect=2.345) coefficients with t 
value of  effect between Bonferroni line are designated as certainly significant 
coefficients with t value of effect between Bonferroni line and t limit linear termed as 
coefficients likely to be significant, while t value of effect below the t limit line is 
statistically insignificant and should be removed from the analysis. The non-
significant response coefficients were deleted and the following significant 
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polynomial response equation(s) for ex-vivo residence time, %CDR at 
  
8
th
 hr and 
cumulative %drug permeation at 8
th
 hr were generated. 
 Ex-vivo residence time  = 11.17+0.86X1+(0.524×[X2])+[0.495×(X3)]+ 
   [0.187×(X1X2X3)]………….eq 3  
 
  %CDR at 8
th
 hr  =  80.41–6.85X1+[–0.964×(X2)]+[–0.959×(X3)]+ 
  [–0.362×(X1X2X3)]………..eq 4 
 
 Cumulative %drug  = 38.63+258X1+[0.663×(X2)]+[0.634×(x3)]+ 
 permeated at 8
th
 hr   [0.240×(X1X2 X3)]……eq 5 
 
 
Validation of experimental design: 
These equations were utilized for validation of the equation of the 
experimental design. An extra design checkpoint formulation (BF9) was prepared and 
the predicted values for ex-vivo residence time, %CDR at 8
th
 hr and cumulative 
%permeation at 8
th
 hr were generated. Experimental values were determined by 
formulating and evaluating BF9, and close resemblance between predicted and 
experimental values indicated validity of generated model. 
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Table 9.32: Evaluation of Extra design check point Formulation BF9 and 
Optimized formulation BF4 
Response parameter 
Formulation 
code 
Predicted 
value 
Experimental 
value 
%RSD 
%CDR at 8
th
 hr BF9 
BF4 
76.39 
80.41 
76.31± 0.51 
84.29 ±0.49 
0.08 
3.88 
Cumulative %permeation 
at 8
th
 hr 
BF9 
BF4 
36.55 
38.63 
37.05 ±0.69 
42.68 ±1.35 
0.5 
4.05 
Ex-vivo residence time 
(hr) 
BF9 
BF4 
10.52 
11.17 
10.68 ±0.51 
11.81 ±0.57 
0.15 
0.74 
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Fig 9.42: Response coefficient significant study on (a)%CDR at 8
th
 hour 
(b)Cumulative %permeation at 8
th
 hour (c)Ex-vivo residence time  
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Interactions studies and response surface plots: 
The possible interactions between X1X2,X2X3,and X1X3 for each response 
were also investigated. The response surface  plots generated using polynominal 
equations represent quantitative simultaneous effect of any two variables at constant 
level. The results were similar to interaction studies but were quantifiable. However 
Design Expert software can analyze both qualitative and quantitative effects of 
variables on the response parameters and hence can facilitative selection of optimized 
formulation. 
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Fig 9.43: Response surface plots showing influence of independent variables 
on response parameter of buccoadhesive formulations %CDR at 8
th
hour 
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Fig 9.44: Response surface plots showing influence of independent variables 
on response parameter of buccoadhesive formulations ex-vivo residence time: 
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Fig 9.45: Response surface plots showing influence of independent variables on 
response parameter of buccoadhesive formulations cumulative %drug permeation at 
8
th
hour. 
Selection of optimized formulation: 
The qualitative and quantitative influence of independent variables on ex-vivo 
residence time, %permeability and %CDR were clearly interpreted from by design 
Expert that is an equally advantageous tool for selection of optimized formulation. 
The tools offer the possibility to vary each variable simultaneously and present 
optimum selections with their respective desirability value. According to our criteria 
of higher %CDR at 8th
 
hour, higher residence time and higher cumulative %drug 
permeated after 8 hour, BF4 was selected as optimized formulation. Consequently ,the 
coded optimized level for the amount of HPMC K4M, concentration of Carbopol 
934P and volume of DMSO for BF4 were identified as -1,+1,and+1 respectively.  
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9.3.14. Stability Study:-  
After storage, the optimized formulation (BF4) was analyzed for various 
physical parameters; results are showed in Table 9.33.  
Table 9.33: Stability studies of Buccoadhesive Film  
Characteristic Initials 1 Month 2 Month 3 Month 
Appearance 
White 
transparent film 
No change No change No change 
Surface pH 7.23 0.08 7.12±0.02 7.10±0.02 7.08±0.02 
Ex-vivo residence time 11.81±0.57 11.28±1.028 11.28±0.01 11.26±0.02 
Ex-vivo drug permeation 
at 8th  hour 
42.68±1.35 40.93±0.64 40.87±0.52 40.32±0.22 
Drug content 98.76± 0.28 97.74 ±0.57 97.37± 0.57 97.27± 0.65 
  *All the values are expressed as mean± SE, n=3. 
         
Fig. 9.46: Comparisons of Surface pH for formulation BF4 with initial and different 
periods of stability 
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Fig. 9.47: Comparisons of Cumulative % drug permeation at 8
th
  hours for 
formulation BF4 with initial and different periods of stability 
 
 
 
Fig. 9.48: Comparisons of  Drug content for formulation BF4 with initial and 
different periods of stability 
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Fig. 9.49: Comparisons of  Ex-vivo residence time for formulation BF4 with initial 
and different periods of stability 
 
No major difference was found between evaluated parameters before and after 
storage and all are in acceptable limits. The Film showed satisfactory physical 
stability at 40°C at 75 % RH. 
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10. SUMMARY AND CONCLUSION 
 
Metoprolol tartrate is a selective β-1 adrenergic antagonist used in the 
treatment of the cardiovascular system, especially Hypertension. 
The present study was aimed to develop a new buccal mucoadhesive system 
for the delivery of Metoprolol tartrate. An attempt was made to formulate Metoprolol 
tartrate buccal film using new mucoadhesive polymers viz. Carbopol 934P, and 
HPMC K4M which have not been tried earlier with this drug. 
Literature review on polymers strongly indicated that polymers selected for 
the present study have bioadhesive and matrix forming properties. Various 
formulations of mucoadhesive buccal Film of Metoprolol tartrate were prepared using 
various polymers in different proportions and combinations. 
The initial part of work was started from the identification of drug. 
Identification of drug was determined by melting point, solubility and FTIR Study. 
The drug polymer interaction study was carried out by DSC study. So, it can be 
concluded that there is no interaction between drug and polymers used in the 
formulations.  
The nine batches of buccal mucoadhesive films of metoprolol tartrate was 
prepared by solvent casting technique. These formulations were optimized using 2 
3
 
factorial design model. 
The formulated Film was evaluated for dimension thickness, weight, folding 
endurance. The observed and obtained information was in the acceptable limits. 
Folding endurance of the formulated films was flexible and displayed good folding 
endurance. 
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The swelling study of film was detailed that maximum degree of swelling was 
observed after 30min. Films containing high level of carbopol 934 P showed high 
degree of swelling; it was beneficial for buccal adhesion. 
The Surface pH of film was found within the range were similar to that of pH 
of saliva in oral cavity. 
The Ex-vivo buccoadhesive strength was performed and the values obtained 
were in the acceptable range except the formulation BF1.    
The Residence time of all batches was studied and result showed that the mean 
adhesion time was increased in the formulation containing Carbopol 934P with 
HPMC K4M.  
The data of In-vitro drug release study indicated that the formulation 
containing Carbopol 934P with HPMC K4M extended the release of the drug and 
these formulations also shown good bioadhesion on goat buccal mucosa. The BF1 and 
BF4 formulation was released the maximum drug at the 8
th
  hour but BF1 was 
rejected due to its less mucoadhesive strength. Hence, Formulation BF4 was the most 
promising formulation as it gives satisfactory drug release upto 8 hours and also 
produced more bioadhesive force as compare to other batch formulations. 
The data of Ex-vivo buccal permeation study explained that the formulation 
containing high of DMSO showed higher permeation of drug in the range obtained 
with formulation BF4. The DMSO has been already reported as effective permeation 
enhancer.  
             The developed buccoadhesive film exhibited sufficient pharmacotechanical 
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 Properties and buccoadhesive character. It was proved by sustaining the drug release 
of water soluble drug like metoprolol tartrate for 8 hr without causing any damage to 
the buccal mucosa. It was also confirmed by the histopathological studies. 
The formulation BF4 had shown the satisfactory release of drug and excellent 
bioadhesive properties. The release data of drug was fitted with the kinetic modeling 
software in order to know the mechanism of drug release. It was found that the 
formulation BF4 follows higuchi model and diffusion mechanism.   
The optimization of prepared films was calculated from design expert 8.0.2 
software. The optimized formulation BF4 was subjected to stability studies, there was 
no appreciable change in the values during the 3 month period of study. 
Hence, from the above information, it was observed that the formulation had 
feasibility of formulating buccal drug delivery in the form of buccal film of 
Metoprolol tartrate as; it can help to bypass extensive hepatic first pass metabolism 
and thus increasing efficacy of Metoprolol tartrate. Buccoadhesive film of 
Metoprolol tartrate was successfully developed to reduce the dosing frequency of the 
drug. The bioavailability of drug can also be improved with this buccoadhesive drug 
delivery system by avoiding extensive first pass effect, increasing efficacy, 
compliance and better clinical usefulness of patients. 
               An optimized formulation BF4 that has the potential to enhance the 
permeability limited   bio availability and to provide a Unidirectional sustained drug 
delivery through the buccal mucosa.  
Hence, from the overall inference, it can be concluded that the formulation 
BF4 was considered as best formulation. 
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11. FUTURE PROSPECTS 
 
The study requires attention of researcher to develop buccal drug delivery 
systems using other bioadhesive polymers and study its permeation through the 
membrane. Furthermore, the study can be extended to evaluate in-vivo performance 
and also In-vitro-In-vivo correlation of the film. 
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